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“Allt stort som skedde i världen, 
skedde först i någon människas fantasi.” 
 
 
“Ibland är det som om livet plockade ut en  
av sina dagar och sa: ‘Dig ska jag ge allt!  
Du ska bli en av de där rosenröda dagarna som 
 skimrar i minnet när alla andra är glömda.’” 
 
 
 
 
- A. Lindgren
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1 ABSTRACT 
Biliary tract cancer, including cancer of the extra-hepatic bile ducts, cancer of the Ampulla of 
Vater and gallbladder cancer, is a devastating disease with poor prognosis. The incidence of 
biliary tract cancer is decreasing worldwide, for unknown reasons. One of two aims of this 
thesis was to evaluate the Swedish Cancer Register regarding biliary tract cancer and to 
assess the incidence of biliary tract cancer in Sweden. Secondly, an association between sex 
hormone exposure, particularly estrogen, and biliary tract cancer has been suggested. Thus, 
the second aim of this thesis was to evaluate the effect of sex hormone exposure on biliary 
tract cancer risk.  
Study I and II were based on data from the Swedish Cancer Register, the Swedish Patient 
Register and the Swedish Causes of Death Register. Study I was a validation study of biliary 
tract cancer diagnoses in the Cancer Register, using data from the Patient Register and the 
Cause of Death Register as comparison. Overall, 44% of patients diagnosed with biliary tract 
cancer between 1990 and 2009 were not found in the Cancer Register. The underreporting 
increased with increasing patient age and later time period. Study II indicated a decreasing 
incidence trend of biliary tract cancer. However, the mortality rates were higher than the 
incidence rates after the mid 1980’s and onwards. Moreover, the incidence trends based on 
data from the Patient Register suggested a more stable or only slightly decreasing trend. 
Thus, even though the incidence of biliary tract cancer may be decreasing, the extent of the 
decline is likely over-estimated. 
Study III investigated the association between reproductive factors and biliary tract cancer. 
Women and men were included in the study, but analyzed separately, to enable 
differentiation between hormone exposure and other factors. The risk of cancers of the extra-
hepatic bile ducts (including the Ampulla of Vater) is likely not influenced by reproductive 
factors because similar associations were seen in women and men. However, an association 
between reproductive factors and gallbladder cancer was observed in women, but not as 
clearly in men. Study IV investigated the risk of biliary tract cancer in a cohort of men with 
prostate cancer, a proxy for estrogen exposure (prostate cancer treatment). There was no clear 
association, although a slightly decreased risk was indicated. However, men with the highest 
presumed estrogen exposure had an increased risk of biliary tract cancer, though the 
association was not statistically significant. Study V investigated the association between 
menopausal hormone therapy and biliary tract cancer. A slightly reduced risk of gallbladder 
cancer was suggested for users of menopausal hormone therapy compared to non-users, but 
the association was not statistically significant. However, an increased risk of gallstone 
disease was noted however.  
In conclusion, there is substantial under-reporting of biliary tract cancer to the Swedish 
Cancer Register, especially in the elderly and in the later time period. The decreasing 
incidence trends of biliary tract cancer in Sweden are likely over-estimated, as a consequence 
of under-reporting. Furthermore, the role of sex hormones in the etiology of biliary tract 
cancer is uncertain. Sex hormone exposure may influence the risk of gallbladder cancer 
specifically but not biliary tract cancer as a whole. Future etiological research should separate 
gallbladder cancer from other extra-hepatic cancers.  
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5 INTRODUCTION 
Biliary tract cancer, referring to cancers of the extra-hepatic bile ducts, the Ampulla of Vater 
and the gallbladder in this thesis, is a rather rare group of diseases in the Western world.(1) 
There are approximately 350 new cases of biliary tract cancer annually in Sweden and the 
incidence has been decreasing world-wide over the past 40 years.(2-4) Less than 30 % of 
patients are eligible for curative surgery at presentation, however, the 5-year survival without 
surgery is less than 10 % in Sweden.(5)  
 
The Swedish Cancer Register is utilized for cancer incidence estimations in Sweden. The 
register has been shown to be of excellent over-all quality, but the completeness for some 
specific cancer sites has been questioned.(6, 7) Incidence estimations based on register data 
will be only as valid as the data themselves. Thus, the first aim of this thesis was to evaluate 
the Cancer Register regarding completeness of biliary tract cancer diagnoses and to estimate 
the incidence of biliary tract cancer in Sweden.  
 
There is a female predominance of biliary tract cancer, specifically for gallbladder cancer 
where the female-to-male ratio ranges between 2 and as high as 5-6 in some countries.(8, 9) 
Often, the association between gallstone disease and biliary tract cancer is cited as an 
explanation.(10) However, estrogen exposure in itself has been suggested to influence biliary 
tract cancer development, but available literature on this matter leaves the research question 
unresolved.(11) Therefore, the second aim of this thesis was to evaluate if sex hormone 
exposure affects the risk of developing biliary tract cancer.  
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6 BACKGROUND 
6.1 BILIARY TRACT CANCER 
6.1.1 History of biliary tract cancer 
One of the first accounts of biliary tract cancer in medical research presented in a systematic 
manner can be found in a paper by the American surgeon Dr. Musser published in the late 
19th century, describing masses of the gallbladder and extra-hepatic bile ducts discovered 
accidentally during laparotomy.(12) Later, during the 20th century, Sako and colleagues 
reviewed the available literature and published a report including 560 cases of biliary tract 
cancer identified between 1935 and 1954 describing the localization and clinical features of 
the disease.(13) Etiological investigations have not been undertaken until more recently but 
the knowledge regarding biliary tract cancer development remains insufficient.  
The treatment of hepatobiliary masses, including distal extra-hepatic cancers, was first 
investigated in the late eighteen hundreds, but was made more systematic by Whipple and 
colleagues when the pancreatico-duodenectomy (later named Whipple’s procedure) was first 
described.(14, 15) Since then, numerous treatment modalities have emerged for managing 
biliary tract cancer, but surgical resection remains the only treatment that may offer a chance 
of cure.(16) In the 19th century, an era when advanced treatment options simply were not 
available, cancers of the biliary tract were effectively a sentence to death. Unfortunately, the 
prognosis for patients who are diagnosed with biliary tract cancer has not improved 
satisfactorily into modern times.(5)  
6.1.2 Clinical presentation, diagnosis and staging 
Clinical presentation 
The clinical characteristics of patients reported by forerunners in biliary tract cancer research 
are recognized in more modern descriptions of the disease. Symptoms typically include 
intermittent pain in the epigastric area or right upper quadrant, anorexia (loss of appetite) and 
nausea.(17) Symptoms of advanced tumor stages of the disease include cholestasis and 
jaundice, due to biliary obstruction, subsequent bacterial translocation with cholangitis and 
sepsis.(10) Secondary symptoms, such as weight loss, fatigue and symptoms from distant 
metastases occur frequently. Because of the slow initial tumor progression, the majority of 
patients present in an advanced stage, when the disease is already locally advanced and/or 
3 
 
systemic.(18) Most patients are diagnosed at older ages and may suffer from other diseases 
and co-morbidities, making a clinical diagnosis even more challenging.(19)  
A subset of patients with gallbladder cancer present with acute cholecystitis (gallbladder 
inflammation) and reports estimate that gallbladder cancer is diagnosed in around 1-2 % of 
patients undergoing cholecystectomy (gallbladder removal) for supposedly benign 
gallbladder disease.(20) However, higher rates have been seen in some case series and in the 
elderly.(21, 22) Conversely, around 8 % of patients with gallbladder cancers are diagnosed 
after routine cholecystectomy for benign gallbladder disease in Sweden.(5)  
Diagnosis 
Acquisition of biopsies for histopathological evaluation of suspected cancerous tissue 
remains an important part of the initial work-up for establishing a correct biliary tract cancer 
diagnosis.(23) The majority of cancers in the biliary tract are carcinomas, mainly 
adenocarcinoma.(5, 24) Access to the biliary tract using minimally invasive procedures is 
limited however, and concerns for tumor dissemination following trans-abdominal biopsies 
have been raised.(25, 26) Available guidelines recommend abdominal ultrasound and routine 
blood work as initial diagnostic tests followed by computed tomography of the abdomen and 
thorax to evaluate tumor stage and the presence of distal metastases.(23) Non-invasive 
imaging techniques, such as trans-abdominal ultrasound, computed tomography and magnetic 
resonance tomography have improved enormously over the past 3 decades, and accurate 
diagnoses can readily be made with these non-invasive methods.(27, 28) Trans-abdominal 
ultrasound is commonly used to evaluate patients with abdominal pain located in the right 
hypochondria and may readily visualize a dilated biliary tree when biliary obstruction is 
present, but the sensitivity for detecting a gallbladder mass may be limited.(27, 29) Computed 
tomography has higher sensitivity for diagnosing malignant obstructions of the biliary tract, 
especially gallbladder cancer when combined with positron emission tomography.(30, 31) 
Furthermore, magnetic resonance imaging is used increasingly with excellent results to 
diagnose biliary tract cancer in a non-invasive manner, but may be inferior to the invasive 
procedure endoscopic retrograde cholangiopancreatography (ERCP).(32-34) 
ERCP is an important modality in biliary tract cancer diagnostics and allows for simultaneous 
tissue sampling; however high false negative rates have been described.(1, 35) More recent 
ERCP-based techniques, including cholangioscopy, have enabled direct visualization of 
cancerous tissue, increasing the diagnostic accuracy.(36) Furthermore, endoscopic ultra-
sound (EUS) has emerged as an important diagnostic modality and is being used increasingly 
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in biliary tract cancer work-up and diagnosis.(37) Additionally, EUS in conjunction with 
fine-needle aspiration, for tissue sampling, has improved the diagnostic accuracy even 
further.(38)  
There are, presently, no reliable biomarkers that offer clear guidance in the differential 
diagnosis of biliary tract cancer. The carbohydrate antigen 19-9 (CA19-9) has been used to 
some extent but studies report lacking performance in the ability to accurately discriminate 
biliary tract cancer from benign lesions.(39) Some reports have suggested that CA19-9 can be 
used as a prognostic marker in advanced biliary tract cancer and to evaluate treatment 
response.(40)  
Staging 
When biliary tract cancer has been confirmed, tumor staging is imperative before patients can 
be assigned a specific treatment, which largely depends on the extent of local tumor growth 
and potential dissemination. In staging of biliary tract cancer, the commonly used TNM 
system for classification developed by the American Joint Committee on Cancer (AJCC), is 
advocated.(41) The T-stage denotes the extent of tumor growth locally, the N-stage assesses 
any lymph node involvement and the M-stage describes if any distant metastases are 
present.(42) Patients are then categorized into TNM group I to IV, depending on tumor 
characteristics. Histo-pathological examination of biopsies in combination with information 
acquired from invasive or non-invasive procedures/imaging techniques form the basis of the 
staging procedure. In cases where curative surgery may come in question, but the extent of 
tumor dissemination is unclear after initial evaluation, staging may involve a diagnostic 
laparoscopy to minimize unnecessary resections.(43)  
6.1.3 Risk factors  
Only a handful of risk factors for biliary tract cancer have been established with variations 
across geographic regions, probably reflecting genetic variations and differences in lifestyle 
risk factors.  
Primary sclerosing cholangitis  
Primary sclerosing cholangitis is an auto-immune, inflammatory disease resulting in strictures 
and stenosis (narrowing) of the bile ducts.(44) Patients diagnosed with primary sclerosing 
cholangitis have an increased risk of developing biliary tract cancer and the incidence of 
primary sclerosing cholangitis is increasing in Europe.(45, 46) The condition itself is 
relatively uncommon, but the etiological contribution to biliary tract cancer may be of 
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importance.(47) There are even reports suggesting that screening of biliary tract cancer in 
patients with primary sclerosing cholangitis may be indicated.(48)  
Diabetes and obesity 
Numerous studies have shown an increased risk of biliary tract cancer, specifically 
gallbladder cancer and extra-hepatic bile duct cancers, in diabetic individuals.(49) In contrast, 
a study based on the European Prospective Investigation into Cancer and Nutrition cohort 
(EPIC cohort) reported an increased risk of gallbladder cancer in diabetic patients, but failed 
to show any clear associations between diabetes and cancers of the extra-hepatic bile 
ducts/Ampullary cancers.(50) A study from Denmark showed an increased risk of biliary 
tract cancer in hospitalized patients with diabetes.(51) Diabetes and obesity often co-exist in 
patients with the metabolic syndrome, which has become an epidemic in the modern Western 
world.(52) However, it has been shown that diabetes increases the risk of biliary tract cancer 
independent of obesity.(53) Conversely, obesity in itself has been reported to increase the risk 
of gallbladder cancer, but not cancers of the extra-hepatic bile ducts or Ampullary 
cancers.(54, 55) Furthermore, the association between obesity and gallbladder cancer may be 
independent of diabetes.(56) An American study revealed an increased risk of cancers of the 
extra-hepatic bile ducts in obese subjects.(57) Additionally, one study showed that obese 
adults appear to have a higher risk of biliary tract cancer-specific mortality; however the 
results were not adjusted for diabetes and there was no differentiation was made between 
tumor locations.(58)     
Gallstone disease 
Gallstone disease (cholelithiasis) normally refers to the presence of gallstones in the 
gallbladder. Gallstones are, most often, formed by precipitation of cholesterol in fat-saturated 
bile but may also consist of other elements such as bilirubin and calcium. However, the 
precise mechanisms behind gallstone formation remains incompletely understood.(59) 
Cholelithiasis is a common condition in Western populations, with an estimated 10-20 % 
prevalence and is one of the most well-documented risk factors for biliary tract cancer.(60-
63) Additionally, cholecystectomy has been shown to decrease the risk of cancers of the 
extra-hepatic bile ducts.(64) However, one Swedish study showed that the risk of cancers of 
the extra-hepatic bile ducts is higher 1-4 years following cholecystectomy, compared to the 
background population, but decreased to the level of the background population over 
time.(61) This finding is likely explained by the relatively large proportion of biliary tract 
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cancers diagnosed en passant after surgery. Cholelithiasis is more frequent in populations 
from South America, where also biliary tract cancer incidence is high.(65)  
Gallstone disease is more common in women, especially in the obese.(66) Furthermore, it has 
been shown that estrogen exposure, i.e. during pregnancy, modulates bile composition, 
gallbladder kinetics and increases the risk of gallstone disease.(67-69) Considering the 
associations between gallstone disease and obesity, diabetes and sex hormone exposure, it has 
been argued that gallstone disease may be seen as a mediator of metabolic, genetic and 
hormonal factors influencing risk for biliary tract cancer development.(53, 70, 71) However, 
about a fifth of all gallbladder cancers removed for histopathological examination have no 
concomitant gallstones.(24) 
Other risk factors 
A number of additional factors have been suggested to influence the risk of biliary tract 
cancer, but may be of limited importance or lack proper support in the literature. More 
specifically, exposure to thorium dioxide (an agent used in radiology in the early 20th 
century), tobacco smoking, Caroli’s disease, certain liver fluke infections (parasitic infections 
mostly limited to Asian populations) and biliary cysts have been described as potential risk 
factors for biliary tract cancer.(10, 57, 72, 73)  
6.1.4 Treatment  
Curative treatment 
Any treatment of biliary tract cancer with a curative intent requires radical surgery.(1) 
Advancements in oncological treatment and minimally invasive procedures have to some 
extent improved the prognosis, but have yet to replace surgical intervention as the corner 
stone of curative treatment.(74) The over-all 5-year survival in patients with biliary tract 
cancer is 5-15% in Sweden.(5) Similar over-all mortality rates have been described 
internationally depending on cancer classification and geographical area.(75-78) At the time 
of biliary tract cancer diagnosis, roughly 25% of patients are considered for surgery in the 
Western world, but some centers have reported a higher rate of curatively intended 
surgery.(1, 5, 79) However, long-term survival is heavily dependent on surgical intervention 
at an early tumor stage.(16) Additionally, tumor stage is a strong predictor of survival. For T1 
gallbladder cancer, where simple cholecystectomy may be enough, the long-term survival in 
operated patients ranges from 65 to 99%.(5, 80, 81) For T2 gallbladder cancer, radical 
cholecystectomy including lymphadenectomy (removal of lymph nodes), bile duct resection, 
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partial hepatectomy (partial removal of the liver) and possibly resection of adjacent organs, 
has been shown to be the correct surgical strategy because the sub-serosal plane, in which the 
dissection for a simple cholecystectomy is commonly performed, is often violated by T2 
tumors.(82) Consequently, the survival of patients with T2 gallbladder cancer ranges from 35 
to 75%.(83, 84) Surgery for gallbladder cancer of stages T3-4 typically involves additionally 
extensive resections and normally a poor long-term survival, ranging from 0 to around 25 
%.(84, 85)  
Curative treatment and prognosis for cancers of the extra-hepatic bile ducts are also strongly 
related with tumor stage. Because of the more heterogeneous anatomical location, surgical 
procedures may involve pancreatico-duodenectomy for more distal tumors or bile duct 
resections with or without partial hepatectomy for more proximal tumors.(18) The 5-year 
survival has been reported to range from 5 to 50% following curatively intended surgery and, 
similarly to gallbladder cancer, less advanced tumor stage is a strong predictor of survival.(5, 
86, 87)  
For advanced biliary tract cancer (stage III and IV) with advanced regional lymph node 
involvement, or when distant metastasis is present, the over-all 5-year survival in Sweden is 
under 10%.(5) Patients with stage IV tumors are seldom selected for surgery because of an 
exceedingly poor prognosis regardless of treatment. There is currently no consensus 
regarding locally advanced disease and resectability, but tumor dissemination to lymph nodes 
around the aorta or further may be a contraindication for curative surgery.(88) However, 
some centers have reported more favorable outcomes even in advanced disease.(89) 
Neoadjuvant treatment typically require biliary drainage via placement of stents in the bile 
ducts in the presence of obstruction in order to decrease the risk of cholangitis and optimize 
patients for surgery.(23, 90) Portal vein embolization may be performed in patients scheduled 
for curative resection including extended hepatectomy when the remnant liver size may be 
insufficient.(91, 92) There is currently no strong evidence to support the use of neoadjuvant 
chemo-radiotherapy in the general management of biliary tract cancer, however some 
benefits have been observed for certain patient categories.(93-96)  
Adjuvant chemo-radiotherapy is sometimes implemented in the treatment of biliary tract 
cancer, however randomized clinical trials evaluating the subject are lacking.(95) One meta-
analysis showed a borderline significant improvement in prognosis when adjuvant therapy 
was employed, and some studies have indicated potential survival benefits in certain patient 
groups.(96, 97)  
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Non-curative treatment 
In the palliative setting, the median survival in patients without specific treatment ranges 
from 3 to 9 months.(98, 99) When obstructive jaundice is present, biliary stenting for bile 
duct patency can increase quality of life and decrease the risk of cholangitis.(100, 101) 
Furthermore, relieve of obstructive jaundice is often a requirement before any specific 
palliative treatment.(88) Recently, a large randomized controlled trial reported a survival 
benefit using a combination of chemotherapeutic drugs compared to a single-drug regimen, 
and provided support for the use of chemotherapy in palliative treatment of biliary tract 
cancer.(102) Photodynamic therapy has emerged as a new treatment modality for 
unresectable biliary tract cancer, however complications are frequent and high-grade 
evidence is lacking.(103) External radiotherapy has been used rather sparsely but may 
prolong survival in some groups.(104) A best supportive care approach, focusing on pain 
management and symptomatic treatment of e.g. nausea and itching may be indicated in some 
patients when specific palliative treatment is inappropriate.(96)  
6.2 CANCER INCIDENCE AND REGISTERS 
6.2.1 Cancer epidemiology  
Epidemiological studies often involve calculating the occurrence of a disease in distinct 
groups. Cancer incidence represents an important measurement of cancer occurrence in 
epidemiological research, and may be used in cancer control programs as well as in academic 
research. In general terms, the incidence of a disease can be defined as the number of new 
cases in a specific population during a specific time period. However, the probability of a 
disease occurring in a specific population during a specific time is sometimes used 
synonymously.(105) Repeated incidence estimations are often calculated at different time 
points in order to monitor incidence changes over time. 
Disease occurrence can be expressed in different ways, yet incidence and prevalence are 
perhaps the most common modalities. Correspondingly, disease incidence may be described 
in different forms, but a distinction into rates and proportions can be made. The concept of an 
incidence rate implies an element of time in the calculations. Mathematically, the numerator 
is the number of new cases in the studied population during the specific time period and the 
denominator is the accumulated observation time of the population at risk. In cancer 
incidence measurements, the observation time is often expressed in person-years. The same 
concept applies to other occurrence measurements, such as mortality rates. Instead of rates, 
various proportions can be calculated to describe the incidence. The incidence proportion can 
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be calculated by dividing the number of incident cases by the size of the population. This 
proportion is equivalent to the risk of the disease. Instead of risk, the odds of a disease 
occurring is the number of new cases in the population divided by the number of disease-free 
individuals at the end of the time period. Time is not directly considered when expressing 
proportions, however the time period where the risk or odds are valid must be specified. 
The second dimension of disease occurrence, prevalence, reflects the number of individuals 
with the disease at a specific time point; mathematically, a proportion. The prevalence is a 
function of incidence and survival/cure rate in combination and is often used in cross-
sectional studies where time is not considered in the same sense as in an incidence estimate. 
However, as with any proportion, it is important to specify the time point at which the 
measurement is taken.  
6.2.3 Cancer registers 
Pioneers in cancer registration first started to catalogue cancer in the mid-20th century and 
currently, more than 200 cancer registers exist worldwide. The International Association of 
Cancer Registries was founded in 1966 and continuously works for a standardized data 
collection procedure to improve comparability between registers of different regions. The 
purpose of cancer registers has traditionally been to collect data on new cancer cases in the 
population and to produce basic statistics about cancer occurrence. However, modern 
authorities have highlighted the synergistic effects of cancer control programs in parallel with 
cancer registers and made arguments that the role of cancer registers could be expanded. 
In Sweden, the National Board of Health and Welfare maintains the national cancer register. 
Incidence and survival statistics are presented annually and reports of changes in cancer 
occurrence over time are presented continuously. Additionally, the cancer register in Sweden 
has been used increasingly in epidemiological research over the past two decades and the 
quality of the register is considered high.(6) However, the number of academic studies 
dedicated to evaluating the quality of data in the cancer registers remains surprisingly low.  
6.2.4 Incidence of biliary tract cancer 
The relative rarity of biliary tract cancer was recognized originally in the 19th century and has 
been confirmed by more recent studies.(4, 9) According to the Swedish Cancer Register, 
approximately 350 patients are diagnosed with biliary tract cancer annually in Sweden, and 
the incidence rate was 3.5 cases/ 100,000 person-years in 2014.(3) The majority of diagnosed 
biliary tract cancers are gallbladder cancers, which are known to be more frequent in women 
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than men.(8) The incidence rates of biliary tract cancer have been decreasing in Sweden over 
the past 25 years.(3)  
Internationally, the incidence of biliary tract cancer is a matter of debate. There is a growing 
body of literature emphasizing the importance of distinguishing the sub-sites of biliary tract 
cancers in analyzing cancer incidence.(4, 106, 107) One recent American study based on data 
from the “Surveillance, Epidemiology and End Results” program showed decreasing 
incidence trends of gallbladder cancer and increasing incidence trends of extra-hepatic 
tumors.(108) Another American study based on different data showed a similar result. (109) 
The incidence of Ampullary cancers specifically, is also decreasing in Europe and in the US. 
(76, 110) Furthermore, a female predominance in gallbladder cancer has been shown in most 
parts of the world.(107, 111) European studies have often reported a decreasing incidence of 
gallbladder cancer, whereas the trends for extra-hepatic tumors are somewhat less clear. A 
number of European studies have shown stable or slightly decreasing incidence of cancers of 
the extra-hepatic bile ducts, excluding gallbladder cancer, whereas some have shown 
increasing trends (112-116) Interestingly, one report has shown an increasing incidence of 
biliary tract cancer in parts of Asia.(117) However, that study was based on data from 
Shanghai in China, an area which may have become more like Western countries over the 
past 30 years due to political/financial changes and may not accurately represent the 
incidence trends for the whole of China.  
The reasons for the seemingly decreasing incidence trends of gallbladder cancer are not well 
understood but have been attributed to the increasing use of cholecystectomy.(4, 24) 
However, evidence of a causal relationship between a more extensive use of cholecystectomy 
and decreased incidence of gallbladder cancer remains scarce, and the decline in gallbladder 
cancer incidence started before the introduction of the laparoscopic cholecystectomy.(8)  
Some reports have highlighted misclassification of biliary tract cancers as a possible 
explanation for differences in incidence trends between registers. (62, 106) However, the 
National Board of Health and Welfare in Sweden have guidelines directing the diagnosis in 
cases where anatomical origin and location is difficult to establish.(118) Yet, the potential 
differences between tumor locations are important to acknowledge in etiological research to 
account for potential biological differences between tumors of the biliary tract.  
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6.3 REPRODUCTIVE FACTORS AND HORMONES 
6.3.1 Sex hormones 
Sex hormones are steroid derivatives involved in numerous physiological functions in the 
human body. Typically, estrogen and progesterone are considered female sex hormones and 
have a primary regulatory role in the menstrual cycle, but are also important in energy 
homeostasis and bone metabolism.(119) Sex hormones are synthesized from cholesterol 
precursors and are regulated by complex feed-back and feed-forward mechanisms involving 
the hypothalamus and the pituitary gland. The levels of estrogen and progesterone vary 
considerably over time, making measurements of hormone levels difficult to interpret in the 
context of accumulated exposure. Therefore, proxies have been used extensively in academic 
research as indicators of hormone exposure. 
6.3.2 Endogenous sex hormones 
Endogenous sex hormones originate from within the body itself in contrast to exogenous 
hormones which are added to the body from external sources. “Reproductive factors” is a 
term often used to describe a number of states or events associated with reproduction, such as 
age at menarche, number of children or pregnancies (parity), age at the birth of the first child, 
age at menopause, and the occurrence of breast feeding. Reproductive factors have been used 
as proxies for endogenous hormone exposure in a variety of studies previously. The rationale 
behind using reproductive factors as proxies for hormone exposure is based on the changes in 
estrogen and progesterone levels women experience during these events. (120) Estrogen 
levels naturally increase during pregnancy to extreme levels.(121) In theory, multiparous 
women (women with more than one child) have been exposed to a higher accumulated dose 
of estrogen over time, compared to a woman with no children. In parallel, estrogen levels 
naturally fall after menopause, and the accumulated estrogen exposure in women 
experiencing early menopause may be lower compared to women with a more normal 
menopausal age.(122) In Sweden, the age at natural menopause has been estimated at around 
50 years, and similar findings have been reported in other European countries.(123-125)   
6.3.3 Exogenous sex hormones 
Hormone therapy is used to treat numerous conditions in modern medicine, ranging from 
contraceptive therapy and menopausal hormone supplementation, to treatment of certain 
types of cancers. The regimens and compounds vary with indication but a disruption of the 
normal hormone homeostasis is the end effect regardless of treatment regimen. An inhibitory 
effect is sometimes desired, which is the case of breast cancer treatment, where estrogen 
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receptor blockers or estrogen synthesis inhibitors are applied to inhibit cancer growth in 
estrogen-dependent tumors.(126) In parallel with the treatment of breast cancer, the treatment 
of prostate cancer with estrogens to achieve androgen deprivation was among the pioneers in 
hormonal cancer treatments. High doses of estrogen were the mainstay treatment for prostate 
cancer until the late 1970’s, when luteinizing hormone releasing hormone agonists were 
introduced.(127) The therapeutic arsenal available in the modern treatment of prostate cancer 
has improved significantly since then to include operative, medical and radiation-based 
techniques making high dose estrogen regimens infrequent.(128)  
One group of patients still exposed to exogenous sex hormones are women with symptoms 
related to hormone deficiency. Menopausal hormone therapy is indicated to relieve vaginal 
atrophy and vaso-motor symptoms in menopausal women, but also as prophylaxis against 
osteoporosis in certain subsets of women.(129) The use of menopausal hormone therapy has 
decreased internationally over the past decades, likely because of the many studies indicating 
an increased risk of breast cancer and cardio-vascular disease in women exposed to hormone 
therapy.(130) Furthermore, the risk of ovarian and endometrial cancer may be increased.(131, 
132) On the contrary, some studies have shown a protective effect of menopausal hormone 
therapy on certain gastrointestinal cancers, such as colon and gastric cancer.(133, 134) Also, 
menopausal hormone therapy increases the risk of developing gallstone disease and 
cholecystitis at standard therapeutic doses.(135)  
6.3.4 Sex hormones in biliary tract carcinogenesis 
Biliary tract cancer, specifically gallbladder cancer, is more common in women than men and 
a role of estrogen has been suggested as an explanation for this sex difference.(136, 137) 
Previous reports have often investigated the effect of endogenous estrogen exposure in 
women using reproductive factors as proxies. The reproductive factors parity and age at the 
birth of the first child have been used previously in medical research as surrogate measures of 
endogenous estrogen exposure.(138, 139) Previous investigations of the association between 
reproductive factors and biliary tract cancer as a whole entity, have reported conflicting 
results. A Norwegian study found no statistically significant association between parity and 
biliary tract cancer and an Italian study showed a non-significant association, but also failed 
to show any association between age at the birth of the first child and biliary tract cancer. 
(140, 141) Studies investigating the association between reproductive factors and gallbladder 
cancer specifically have been more consistent, showing an increased risk with increasing 
parity.(70, 142-147) Similarly, older age at the birth of the first child has also been shown to 
be inversely associated with gallbladder cancer.(70, 146, 147) One study investigated the 
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effect of age at the last birth and found a positive association with gallbladder cancer.(143) 
Investigations in cancers of the extra-hepatic bile ducts excluding gallbladder cancer have 
failed to show any statistically significant associations.(57, 70, 147)  
Early menarche, late menopause and menopausal status have been shown to increase the risk 
of biliary tract cancer in some studies, supporting the “hormonal hypothesis”.(57, 137, 143, 
147, 148) However, some studies have failed to confirm the results.(141, 149) Some studies 
even reported later menarche to be a risk factor for gallbladder cancer. (57, 145, 147) It is 
possible that differences in study design, study population, or classification of exposure or 
outcome may have contributed to the inconsistencies.  
The risk of developing biliary tract cancer following exogenous hormone exposure has not 
been studied to a great extent and the available literature does not provide a coherent picture. 
Some studies have demonstrated an increased risk of biliary tract cancer after hormone 
replacement therapy for menopausal symptoms or oral contraceptives.(150, 151) However, 
opposite results have been observed in some studies and some studies have failed to show 
any clear associations whatsoever.(57, 146, 152-154) Failure to discriminate between 
gallbladder cancer and other extra-hepatic tumors may in part account for the differences 
between studies. Furthermore, it has been shown that exogenous hormone exposure 
modulates bile composition and increases the risk of cholelithiasis, benign gallbladder disease 
and biliary tract surgery, suggesting a pathway for biliary tract carcinogenesis by exogenous 
estrogen exposure via gallstone disease.(155-157) 
Investigations in the molecular changes in biliary tract cancer have provided further proof of 
a role of sex hormones in the etiology of biliary tract cancer. It is known that estrogen-
mediated processes regulate cholangiocyte (cells of the bile duct) proliferation under 
physiological conditions and more recently, that estrogen is important in the pathophysiology 
of the bile ducts in biliary tract cancer.(158) In vitro studies have shown that estrogen 
exposure increases cancer cell growth in bile duct cancer cells and that Tamoxifen (an 
estrogen receptor antagonist) inhibits cancer cell growth.(159, 160) Furthermore, histological 
evaluations of gallbladder cancer tissues have revealed increased expression of estrogen 
receptors, and anti-hormonal therapies have been suggested as a potential treatment target for 
biliary tract cancer.(161) Moreover, genetic alterations in genes involved in estrogen 
regulation have been associated with the risk of biliary tract cancer.(162, 163)   
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7 AIMS OF THIS THESIS 
The overall aims of this thesis were to clarify the incidence of biliary tract cancer in Sweden 
and to investigate the role of sex hormone exposure in biliary tract cancer etiology.  
 The specific aims were: 
• To investigate the completeness of the Swedish Cancer Register regarding biliary 
tract cancer. 
• To evaluate the incidence trends of biliary tract cancer in Sweden. 
• To clarify if parity or age at the birth of the first child (proxies for endogenous sex 
hormone exposure) influence the risk of biliary tract cancer. 
• To examine the risk of biliary tract cancer in men exposed to exogenous estrogen 
during prostate cancer treatment.  
• To assess the association between menopausal hormone therapy and the risk of biliary 
tract cancer.  
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8  DATA SOURCES AND METHODS 
8.1 OVERVIEW 
Table 1. Overview of materials and methods used in Studies I-V. 
 Study I Study II Study III Study IV Study V 
Study 
design 
Population-
based 
validation 
study 
Population-
based 
incidence study 
Population-
based case-
control study 
Population-
based cohort 
study 
Population-
based cohort 
study 
Data 
sources 
The Swedish 
Cancer 
Register, the 
Swedish 
Patient 
Register and 
the Swedish 
Causes of 
Death 
Register 
The Swedish 
Cancer 
Register, the 
Swedish 
Patient 
Register and 
the Swedish 
Causes of 
Death Register 
The Swedish 
Cancer 
Register, the 
Swedish 
Patient 
Register, the 
Swedish 
Causes of 
Death Register, 
the Multi-
Generation 
Register and 
the Register of 
the Total 
Population 
The Swedish 
Cancer 
Register, the 
Swedish 
Patient 
Register, the 
Swedish 
Causes of 
Death Register 
and the 
Register of the 
Total 
Population 
The Swedish 
Cancer 
Register, the 
Swedish 
Patient 
Register, the 
Swedish 
Causes of 
Death Register 
and the 
Prescribed 
Drug Register 
Source 
population 
All Swedish 
residents 
All Swedish 
residents 
Individuals in 
the Multi-
Generation 
Register 
Men with 
prostate cancer  
Swedish 
women in the 
Prescribed 
Drug Register  
Time 
period 1990-2010 1970-2010 1960-2008 1961-2008 2005-2012 
Exposure N/a N/a 
A) Parity                            
B) Age at the 
birth of the first 
child 
Prostate cancer 
treatment  
Menopausal 
Hormone 
Therapy 
Outcome Biliary tract cancer 
A) Biliary tract 
cancer           
B) Gallbladder 
cancer 
A) Biliary tract 
cancer             
B) Gallbladder 
cancer             
C) Cancers of 
the extra-
hepatic bile 
ducts/Ampulla 
A) Gallbladder 
cancer             
B) Cancers of 
the extra-
hepatic bile 
ducts/Ampulla  
A) Gallbladder 
cancer             
B) Cancers of 
the extra-
hepatic bile 
ducts/Ampulla  
Statistical 
methods 
Frequency 
distributions 
and relative 
proportions 
Standardized 
incidence rates 
and join-point 
regression 
Conditional 
logistic 
regression 
Standardized 
Incidence 
Ratios  
Conditional 
logistic 
regression and 
Cox 
Proportional 
Hazards 
models 
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8.2 DATA SOURCES 
The five studies that are included in this thesis are based on data from Swedish national 
health-care registers. Record linkage between the registers was made possible by the use of 
the Swedish personal identity number uniquely identifying all Swedish residents.(164) In all 
the included studies, the patient data have been made anonymous to adhere to patient 
integrity regulations.  
8.2.1 The Swedish Cancer Register 
The Cancer Register was established in 1958 and collects data on newly diagnosed cancers in 
Sweden. The register is kept by the National Board of Health and Welfare. Since the 1980’s 
however, newly diagnosed cancers are typically reported to one of six regional cancer 
registers, spread out across Sweden, where each case undergoes routine controls and 
subsequent data registration. Thereafter, in October each year, the regional cancer registers 
submit the registered data from the preceding year to the national register at the National 
Board of Health and Welfare.(165) The regional centers use structured procedures for 
inputting new data and perform basic operations to ensure the correctness of the data. There 
is no direct communication between the Cancer Register and other health-care registers such 
as the Patient Register or the Causes of Death Register. One important implication of this 
lack of communication is that a cancer diagnosis reported in one of these other register will 
not automatically be registered in the Cancer Register. This characteristic has important 
implications for academic research comparing the registers to one another. However, health-
care practitioners in Sweden are required by law to report newly diagnosed malignant tumors 
and some benign tumors to the register regardless of the foundation of the diagnosis. 
Additionally, pathology departments are also required to report tumors diagnosed during 
histopathological and cytological examinations of specimens collected from tissue sampling. 
Thus, in the case of histologically verified cancers, newly reported cases should have two 
independent registrations. 
The Cancer Register contains data about the cancer diagnosis according to the 7th version of 
the International Classification of Diseases (ICD), date of diagnosis, tumor stage, 
histopathology (when collected), foundation of the diagnosis, patient characteristics and 
information about the health-care facility where the diagnosis was made.   
Recently, concerns that clinicians less often report new cancer cases unless verified by 
histopathology have been raised.(166) However, histopathological confirmation is not a 
requirement for registration in the Cancer Register. Under-reporting of cancer could seriously 
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influence the completeness of the data in the Cancer Register and thereby its usability in 
epidemiological research. The Cancer Register has been evaluated in only a handful of 
studies. Mattson et al. reported a non-reporting of less than 2% in the latter part of the 1970’s 
in a comparison with death certificates.(167) A more recent study showed that the overall 
completeness is high (96%), but also that existing under-reporting seems to be site-dependent 
and also increases with age.(6)  
8.2.2 The Swedish Patient Register 
The Patient Register was first established in the 1960’s to collect data on in-patient care, 
psychiatric care in particular. The scope of the register was extended and became nationwide, 
capturing all in-patient care, from 1987 onwards. Furthermore, data from specialized out-
patient visits from public and private health care providers are also available from 2001 
onwards. The data collected by the register includes discharge diagnoses according to the 
current version of the ICD, surgical procedures, patient characteristics (age, sex etc.) and 
administrative information, such as data about the health care provider and date of 
admission.(169) The quality and reliability of the Patient Register has been evaluated by the 
National Board of Health and Welfare and others, and the positive predictive value of a 
diagnosis in the Patient Register is approximately 90%.(170) 
8.2.3 The Swedish Causes of Death Register 
The Causes of Death Register collects information about all deaths among Swedish residents 
and even though the collection of mortality statistics in Sweden started much earlier, the 
register in its current shape was established in the 1960’s. The register is maintained by the 
National Board of Health and Welfare and is believed to cover more than 99 % of all 
Swedish residents.(171) Every person registered as a Swedish resident at their time of death 
should, at their time of death, be reported to the Causes of Death Register, regardless of the 
place of death. The data in the register are based on death certificates, containing not only 
patient data but also primary and underlying causes of death. Typically, it is the responsibility 
of the physician who acknowledges the death to sign and submit the death certificate after 
making an ample evaluation of the cause of death. The physician specifies the immediate 
cause of death and potential underlying causes of death in the certificate. The quality of the 
register is, to a large extent, determined by two key factors intimately linked to the production 
of the death certificate, the rate of non-reporting and the correctness and completeness of the 
death certificates. Firstly, the rate of non-reporting is low, but has increased from less than 
1% in the 1980’s to almost 3% in 2008. Moreover, less than 1% of all death certificates are 
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incomplete or inadequately specified. Secondly, there is substantial variation in the quality of 
the issued death certificates. Malignant tumors, specifically, have been found to be correctly 
specified as the cause of death in around 90% of all cases.(171)  
The reliability of cause of death statistics is sometimes suggested to correlate with the 
autopsy rate. In Sweden, the autopsy frequency has decreased from around 50% in the 1970’s 
to only 12% in 2009. However, improvements in diagnostic instruments, such as laboratory 
tests and imaging, may allow for a reliable diagnosis to be made without the need for a 
clinical autopsy. Therefore, it is not likely that the quality of statistics concerning causes of 
death have decreased to the same extent as the autopsy rates.(171) 
8.2.5 The Register of the Total Population and the Multi-Generation Register 
The Register of the Total Population is one of the major population registers available in 
Sweden and is maintained by Statistics Sweden. All Swedish residents are included in the 
register and are identified by the personal identity number. Data such as birth date, sex, 
marital status, birth country, educational level, and migration can be extracted from the 
register. The register is of high overall quality and completeness should not be a major 
concern for the use of the register in most epidemiological research.(172) The Multi-
Generation Register is a subset of the Total Population Register and contains data on the 
family connection between parents and offspring. The number of children and age at the birth 
of each child can be extracted from the register. The register contains data on more than 9 
million individuals and the coverage of parenthood is more than 98 % from 1961 
onwards.(173) Due to lack of data for some time periods, individuals born in 1932 who died 
before 1961 may be missing from the register.  
8.2.6 The Swedish Prescribed Drug Register 
The Prescribed Drug Register was established in 2005 and has since then collected 
information about all dispensed drugs in Sweden. The register is maintained by the National 
Board of Health and Welfare. According to Swedish law, pharmacies are required to submit 
data regarding dispensed drugs to the Electronic Health Authorities, where a basic control of 
the data is completed. The data are submitted electronically and the information is then 
submitted to the National Board of Health and Welfare for entry into the register. Data 
submission occurs on a monthly basis and includes the dispensed item and dosage, dispense 
date, the personal identity number, the Anatomical Therapeutic Chemical (ATC) code of the 
drug etc. Over-the-counter drugs and drugs used in in-patient care are not included in the 
register.(174)   
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8.3 STUDY DESIGN AND METHODS 
8.3.1 Study I 
To evaluate the completeness of the Cancer Register, Study I compared biliary tract cancer 
records in the Cancer Register with biliary tract cancer records in the Patient Register 
between 1987 and 2010. Three sub-populations were thus created:  
1) patients with records in both registers (CR-and-PR);  
2) patients with records in the Patient Register only (PR-not-CR) and;  
3) patients with records in the Cancer Register only (CR-not-PR).  
Furthermore, the cause of death, assessed from the Causes of Death Register, were compared 
with the cancer records in the three sub-populations to evaluate the accuracy of biliary tract 
cancer diagnoses. Biliary tract cancer was identified by the ICD-7 codes 1551-1559. Biliary 
tract cancer cases in the Cancer Register with a diagnosis based on an unexpected finding on 
autopsy records only were excluded because of the unlikeliness that these patients would 
have a concordant entry in the Patient Register. Further exclusions were made for biliary tract 
cancer diagnosed before the study period and a registered death before cancer diagnosis. Case 
registration in each register is independent of registration in the other two. 
8.3.2 Study II 
Building on the results of the first study, Study II assessed the incidence and mortality trends 
of biliary tract cancer in Sweden between 1970 and 2010 using the Cancer Register, the 
Patient Register and the Causes of Death Register. For the Patient Register specifically, the 
data acquisition was limited to the years 1987-2010 because of the incomplete national 
coverage of the register before 1987. Cancer of the extra-hepatic bile ducts was identified by 
the diagnosis codes 155.2, 156.11, 156B and C24.0 in the ICD-7, ICD-8, ICD-9 and ICD-10, 
respectively. Corresponding codes identifying ampullary cancer were 155.3, 156.21, 156C, 
C24.1, and for gallbladder cancer the codes 155.1, 156.01, 156A and C23.9 were used. 
Furthermore, the codes 155.8-155.9 156.99, 156W-X and C24.8-9 denoted biliary tract 
cancer without clear origin or with extensive growth.  
8.3.3 Study III 
Study III was a case-control study, nested with the Multi-Generation Register, investigating 
the association between reproductive factors and biliary tract cancer. The Cancer Register, 
Patient Register, Causes of Death Register and the Register of the Total Population provided 
data of cancer diagnoses, comorbidities, date of death, educational level and migration status, 
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respectively. The study period was between 1960 and 2008. Previously cancer-free women 
and men, above 15 years of age, with a first diagnosis of biliary tract cancer identified in the 
Cancer Register were considered cases. Biliary tract cancer was denoted by the ICD-7 codes 
1551-1553 (Table 2). Furthermore, only adenocarcinomas, denoted by the histology code 096 
(WHO C24.1 coding system) were included to ensure uniform tumor biology. Ten age- and 
sex-matched controls were randomly selected for every incident case using density-based 
sampling.(175) Subjects with a history of cholecystectomy were not eligible as controls for 
the gallbladder cancer specific analysis. To be eligible, controls had to be resident in Sweden, 
alive at the time of the cancer diagnosis of the corresponding case and have no previous 
history of gastro-intestinal malignancy. Parity (number of children) and age at the birth of the 
first child were the study exposures and were used as proxies for endogenous sex hormone 
exposure. The study end-points were biliary tract cancer, death, migration, or end of study 
period, whichever occurred first. Women and men were included, but analyzed separately.  
8.3.4 Study IV 
This was a population-based cohort study that investigated the risk of biliary tract cancer in a 
cohort of men exposed to exogenous estrogen. The cohort consisted of men with a 
histologically verified diagnosis of prostate cancer between 1961 and 2008 identified in the 
Cancer Register. The ICD-7 code 177 identified prostate cancer. Prostate cancer diagnosis 
was used as proxy for exogenous estrogen exposure. The cohort was a priori divided into two 
groups, based on time period, to account for the changes in prostate cancer treatment 
occurring during the study period. Before 1980, prostate cancer was typically treated with 
high-dose estrogen regimens to achieve androgen deprivation, whereas less estrogen-heavy 
treatments gained ground after 1980.(127, 128) The cohort was thus split into an early, and 
more estrogen exposed group (1961-1980), and a later, and less estrogen exposed group 
(1981-2008). The outcome was histologically verified adenocarcinoma of the biliary tract 
cancer, identified in the Cancer Register by the ICD-7 codes 1551-1553 and the histology 
code 096 (WHO C24.1). The risk of biliary tract cancer in the two periods was compared to 
the risk in the general male population. Potential confounding factors, death and migration 
were assessed from the Patient Register, the Causes of Death Register and the Register of the 
Total population, respectively.  
8.3.5 Study V 
Study V was a cohort study investigating the association between menopausal hormone 
therapy and biliary tract cancer in Swedish women between 1st of July 2005 and 31st of 
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December 2012. The cohort was based on data from the Prescribed Drug Register and 
included all women exposed to menopausal hormone therapy between 1st of July 2005 and 
31st of December 2011, and women identified in the Prescribed Drug Register without such 
therapy. The register contains information about more than 90% of all Swedish women 
between 40 and 64 years of age, and more than 95% of women aged 65 years or more. 
Women with a history of cancer prior to the start of the study, assessed form the Cancer 
Register, were excluded.  
The cohort was initially constructed using a comprehensive matching procedure, first on 
group level at a 1:3 ratio. Thus, 3 unexposed women were selected for each exposed woman. 
Study participants were matched exactly for three variables: history of delivery (yes/no), 
hysterectomy (yes/no) and history of thrombotic events (yes/no), producing eight strata. 
Thereafter, additional matching for age (year of birth), diabetes (yes/no), alcohol-related 
disease (yes/no), obesity (yes/no), and smoking-related disease (yes/no), using the nearest 
neighbor strategy were performed within each stratum. The extensive matching, even for 
factors not strongly related to hormone therapy and biliary tract cancer was undertaken to 
capture effects of potential confounding from unmeasured factors. Matching variable status 
were assessed from the Patient Register. ICD-codes for the matching variables are presented 
in Table 2.  
Women with at least one prescription of a drug used for systemic menopausal hormone 
therapy were considered exposed. Women exposed to hormone therapy before 40 years of 
age before the start of the study were excluded. The ATC codes “G03C” and “G03F” were 
used to identify estrogen containing drugs used for treatment of menopausal symptoms. Only 
systemic (oral or transdermal) preparations were considered. The cohort was followed-up for 
adenocarcinoma of the biliary tract, assessed from the Cancer Register. Gallbladder cancer 
and cancers of the extra-hepatic bile ducts and the Ampulla were identified by the 
corresponding ICD-10 codes (Table 2). Adenocarcinoma was denoted by the code “096” 
(WHO C24.1 definition). For gallbladder cancer specifically, women with cholecystectomy 
prior to the start of the study were excluded because they would not be at risk. 
Secondly, an unmatched cohort was constructed using the same data sources as described 
above, but the matching procedure was omitted. All women identified in the Prescribed Drug 
Register were included in the unmatched cohort. The outcome was classified according to the 
ICD-7 (Table 2). Exclusions were the same as for the matched cohort. 
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Table 2. Diagnoses codes of variables used in Studies I-V, by ICD version. 
Variable ICD-7 ICD-8 ICD-9 ICD-10 
          
Outcomes         
Gallbladder cancer 1551 156,01 156A 23.9 
Cancers of the extra-
hepatic bile ducts 1552 156,11 156B 24.0 
Ampullary cancer 1553 156,21 156C 24.1 
Biliary tract cancer, 
other 1558-9 156,99 156W-X 24.8-9 
Matching/confounding variables        
Delivery 660'-678' . . . 
Diabetes mellitus 260' 250' 250' E10.0-E11.9 
Obesity 287' 277' 278' E65.9-E66.9 
Primary sclerosing 
cholangitis Not defined Not defined Not defined K83.0A 
Alcohol-related 
disease 
307', 322.0-
322.2, 581.1 
291.1-3, 291.9, 
303.0-303.2, 
303.9, 571.0 
303', 305A, 357F, 
425F, 535D, 980', 
291', 571A-571D 
T51.9, F10', G31.2, 
K29.2, K70', 
K86.0, R78.0, 
Z71.4, K85.2, 
E24.4, G62.1, 
G72.1, I42.6 
Smoking-related 
disease 
450', 451', 
501.99-505.00, 
527.10-527.11 
440', 441', 443.9-
445, 490.9-491, 
492 
440', 441', 557B, 
490', 491' 
I70', I71', I73, 
K55.1, J41', J42', 
J43', J44 
Gallstone disease 584' 574' 574' K80', K85.1, K56.3, K81 
Thrombotic events .  451', 452', 453', 450' 
451', 452', 453', 
415' I80', I81', I82', I26' 
Surgical procedures         
Cholecystectomy .   . 5350-5359 a JKA20, JKA21 a 
Hysterectomy .  .  7210-7228 b LCD00-97 b 
a 6th classification of surgical procedures (1963-1996), b KVÅ97 (1997-) 
 
8.4 STATISTICAL ANALYSES 
8.4.1 Study I 
Firstly, relative proportions in the three sub-populations were calculated as a measure of 
concordance between the Cancer Register and the Patient Register. The cancer date in the 
Cancer Register was used as the index date. In cases reported to the Patient Register only, the 
date of first admission with cancer as the discharge diagnosis was used as the index date.  
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Secondly, the results were stratified by sex, age group (<60, 60-69, 70-79, or ≥80 years of 
age), and 5-year calendar periods (1990-1994, 1995-1999, 2000-2004, or 2005-2009). The 
analyses were restricted to 1990 and onwards to ensure that each date of cancer occurrence 
was the first reported cancer diagnosis in the Patient Register. 
Thirdly, the concordance between the cause of death and biliary tract cancer diagnosis in the 
three sub-populations was calculated and the analysis was stratified for number of hospital 
discharges with a biliary tract cancer diagnosis (1,2,3,4, or ≥5). Cause of death was 
categorized into seven groups: pancreatic cancer, biliary tract cancer, esophageal or gastric 
cancer, liver cancer, metastatic or advanced cancer, non-gastrointestinal, and non-malignant 
disease.  
Lastly, the survival probability in relation to the time since biliary tract cancer diagnosis was 
calculated for the three sub-populations.  
8.4.1 Study II 
Annual incidence and mortality rates of biliary tract cancer per 100,000 individuals between 
1970 and 2010 were calculated. Rates were age-specific and age-adjusted. For the Patient 
Register, incidence rates were calculated from 1990 onwards, to prevent inclusion of 
prevalent cases before the register became nationwide. Each year’s age distribution was used 
in the denominator and incidence/mortality rates were standardized using the Swedish 
background population in 2010 as a reference. Analyses were made for biliary tract cancer as 
a whole, but also for gallbladder cancer separately.  
The results from the Cancer Register were further stratified on the basis of the diagnosis and 
which were categorized into five groups:  
1. Radiology-based; 
2. histopathology after biopsy; 
3. cytology-based; 
4. autopsy findings; 
5. surgery/autopsy without histopathology, clinical or laboratory findings. 
To analyze trends of incidence/mortality over time, log-linear joinpoint regression was used 
to calculate Annual Percent Change (APC) with 95% Confidence Intervals (CI) to detect 
statistically significant trends changes.  
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8.4.1 Study III 
Conditional logistic regression was used to calculate Odds Ratios (OR) with 95% CI to 
estimate the association between reproductive factors and biliary tract cancer. Cancer of the 
extra-hepatic bile ducts, ampullary cancer and gallbladder cancer were analyzed separately. 
Parity was categorized into four groups: 0, 1, 2, or ≥3 and subjects with one child were used 
as reference category. The age at the birth of the first child was categorized into three groups: 
≤22, 23-29, or ≥30 years of age and subjects aged 22 years or less at the birth of the first child 
were used as the reference category.  
The statistical model included the matching variable age and further adjusted for 
comorbidities (binary), country of birth (Sweden or outside Sweden), and level of education 
(four categories: elementary school, secondary school, university or missing). Comorbidities 
included diabetes, alcohol abuse, and smoking-related diseases. Only a very small number of 
cases (eight in total) had a history of primary sclerosing cholangitis and therefore no 
adjustment was therefore performed for this condition. 
To address any potential effect of menopausal status, the analyses were stratified for age at 
cancer diagnosis/index date. Thus, study subjects aged less than 50 years were compared with 
subjects aged 50 years or more. However, because of the limited sample size, the effect of 
menopausal status was analyzed for gallbladder cancer only. 
8.4.1 Study IV 
Standardized incidence ratios (SIR) with 95% CI were calculated as the ratio of the observed 
to expected number of newly diagnosed biliary tract cancers. The expected number of cancers 
was the product of the age- and calendar year-specific incidence rate and the observed 
number of person-years in the Swedish male population, using five-year intervals. The two 
groups of the cohort were followed until biliary tract cancer diagnosis, emigration, death, or 
the end of the study period; whichever occurred first. To reduce potential surveillance bias, 
the first year of follow-up was discarded.  
Cancers of the extra-hepatic bile ducts and ampullary cancer were analyzed as one entity and 
gallbladder cancer was analyzed separately. For the gallbladder cancer analysis specifically, 
cases with a history of cholecystectomy prior to the start of the study were excluded. 
Furthermore, cholecystectomy represented an additional outcome.  
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To evaluate a potential effect of confounding factors, sensitivity analyses excluding 
individuals with obesity, diabetes, primary sclerosing cholangitis, alcohol related disease, and 
gallstone disease without record of cholecystectomy were performed.  
Finally, to address any effect of a prolonged exposure, the analyses were stratified by latency 
time between diagnosis of prostate cancer and biliary tract cancer. Latency time was 
categorized into two groups: >1-5 years and >5 years.  
8.4.1 Study V 
The matched cohort 
The association between menopausal hormone therapy and biliary tract cancer in the matched 
cohort was evaluated using conditional logistic regression models, calculating an OR with 
95% CI. The cohort was followed-up for adenocarcinoma of the biliary tract. Gallbladder 
cancer was analyzed separately and cancers of the extra-hepatic bile ducts were analyzed 
together with ampullary cancers. End-points were biliary tract cancer, end of follow-up, death 
or diagnosis of a cancer other than biliary tract cancer, whichever occurred first.  
The exposure, menopausal hormone therapy, was categorized as a binary variable 
(ever/never), i.e. prevalent users at the start of follow-up in 1 July 2005 and women ever 
exposed to menopausal hormone therapy during the follow-up were included. The analyses 
were further stratified for the type of regimen (estrogen only or combination regimen). 
The multivariable logistic regression model accounted for the variables used in the matching 
procedure, which is appropriate if the models are adjusted for factors other than the matching 
variables.(176) The model was further adjusted for osteoporosis. 
Additionally, to evaluate the effect of gallstone disease on the association between hormone 
therapy and gallbladder cancer, individuals with a history of gallstone disease prior to the 
start of the study were excluded. Additionally, gallstone disease was used as an outcome in a 
second regression model to assess the association between hormone therapy and gallstone 
disease.  
The unmatched cohort 
In the unmatched cohort, the association between biliary tract cancer and menopausal 
hormone therapy was assessed using Cox proportional hazard models, providing hazard ratios 
(HR) with 95 % CI. Person-years were calculated from the start of the study until registered 
biliary tract cancer, end of follow-up (December 31st 2012), or death, whichever occurred 
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first. Moreover, cohort members were censored if diagnosed with a malignancy other than 
biliary tract cancer. For gallbladder cancer specifically, date of cholecystectomy represented 
an additional censor point. The proportional hazards assumption was tested on the basis of the 
Schoenfeld residuals. There was no deviation from proportional hazards noted.  
The exposure was categorized as ever/never and was included as a time-dependent variable to 
account for changes in exposure over time. The analyses were stratified according to the type 
of MHT regimen, either estrogen only or estrogen/progestogen combinations. The 
multivariable analyses were adjusted for age (year of birth), diabetes (yes/no), primary 
sclerosing cholangitis (yes/no), hysterectomy (yes/no) and gallstone disease (yes/no) (Table 
2). Gallstone disease was included as a covariate to address the effect of hormone therapy on 
biliary tract cancer, accounting for the expected increased frequency of gallstone disease in 
the exposed. To make detection of all outcomes possible, biliary tract cancers diagnosed 
within a 90-day window after cholecystectomy were considered in the analyses. 
8.5 SOFTWARE FOR STATISTICAL ANALYSES 
Statistical analyses of Studies I, III and IV were performed using SAS Statistical Package, 
version 9.2 (SAS Institute Inc., Cary NC, USA.) 
Statistical analyses for Studies II and V were performed using STATA 13 statistical software 
(StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP.).  
Joinpoint analysis in Study II was performed using SEER*Stat (Surveillance Research 
Program, National Cancer Institute SEER*Stat Software [seer.cancer.gov/seerstat] version 
4.3.1.0. 
8.6 ETHICAL CONSIDERATIONS 
The Regional Ethical Review Board in Stockholm has approved all studies in this thesis. 
Studies I to V are strictly register-based and there has been no contact with individual patients 
or control subjects. All data about the study subjects have been made anonymous before 
presented to the researcher’s making reverse identification of study participants impossible. 
All results are presented at group level to prevent any identification of the study participants. 
Data storage, management and analyses have been performed on firewall- and password 
protected servers at Karolinska Institutet, and located in secure offices accessed by key card 
and password. 
 
27 
 
9 RESULTS 
9.1 STUDY I 
9.1.1 Concordance between the Cancer Register and the Patient Register 
In total, 14,273 biliary tract cancer cases were identified in the Cancer Register and/or the 
Patient Register (Figure 1 and Table 3). Overall, 44% (6,303) of the study subjects were 
identified in the Patient Register only. Correspondingly, 48% (6,799) of the study subjects 
were identified in both registers. A total of 8% (1,171) were identified in the Cancer Register 
only. The vast majority of the biliary tract cancer cases (92%) were identified in the Patient 
Register. 
 
 
Figure 1. Distribution of biliary tract cancer cases in the Cancer Register (CR) and the 
Patient Register (CR) between 1990 and 2010. PR-not-CR: Cases in the Patient Register 
only. CR-and-PR: Cases in both registers. CR-not-PR: Cases in the Cancer Register only.  
 
Biliary tract cancer patients were more often women, and women were somewhat more 
frequently reported to the Cancer Register (58%) compared to men (52%) (Table 3). 
Additionally, most of the study subjects were 70 years or older at the time of cancer diagnosis 
(63%). In parallel, subjects aged 80 years or more were less often reported to the Cancer 
Register (46%) compared to subjects aged less than 60 years (59%). The absolute number of 
new cases was relatively stable over the study period but only 43% of study subjects 
diagnosed between 2005 and 2009 were registered in the Cancer Register, compared to 73% 
diagnosed between 1990 and 1994. 
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Table 3. Number of patients with biliary tract cancer diagnosis in the Swedish Cancer Register 
(CR) and the Swedish Patient Register (PR) between 1990 and 2009. 
  Total PR CR CR-and-PR PR-not-CR CR-not-PR 
Total, (%) 14,273 (100) 13,102 (92) 7,970 (56) 6,799 (48) 6,303 (44) 1,171 (8) 
Sex, (%)             
  Male 5,348 (100) 4,899 (92) 2,786 (52) 2,337 (44) 2,562 (48) 449 (8) 
  Female 8,925 (100) 8,203 (92) 5,184 (58) 4,462 (50) 3,741 (42) 722 (8) 
Age, (%)               
  <60 2,051 (100) 1,886 (92) 1,218 (59) 1,066 (52) 833 (41) 152 (7) 
  60-69 3,207 (100) 2,944 (92) 1,995 (62) 1,732 (54) 1,212 (38) 263 (8) 
  70-79 4,863 (100) 4,425 (91) 2,849 (59) 2,419 (50) 2,014 (41) 430 (9) 
  ≥80 4,152 (100) 3,847 (93) 1,908 (46) 1,582 (38) 2,244 (54) 326 (8) 
Time period, 
(%)     		       
  1990-1994 3,454 (100) 2,989 (87) 2,515 (73) 2,072 (60) 939 (27) 443 (13) 
  1995-1999 3,428 (100) 3,161 (92) 2,030 (59) 1,758 (51) 1,398 (41) 272 (8) 
  2000-2004 3,650 (100) 3,413 (94) 1,804 (49) 1,572 (43) 1,846 (51) 232 (6) 
  2005-2009 3,741 (100) 3,539 (95) 1,621 (43) 1,397 (37) 2,120 (57) 224 (6) 
PR-not-CR: Cases in the Patient Register only. CR-and-PR: Cases in both registers. CR-not-PR: Cases in the 
Cancer Register only. 
 
9.1.2 Concordance between the Cancer Register, the Patient Register and the Causes of 
Death Register 
Altogether, 93% of all study subjects died during the study period and the distribution was 
similar in all three sub-populations (Table 4). The overall concordance between biliary tract 
cancer diagnosis and biliary tract cancer as cause of death in the sub-population identified in 
both registers was 84%. Corresponding agreement for the sub-populations reported to the 
Patient Register or the Cancer Register only was 59% and 51%, respectively. The 
concordance between biliary tract cancer diagnosis and biliary tract cancer as the cause of 
death, increased with an increasing number of hospital discharges with a diagnosis of biliary 
tract cancer in both sub-populations, where such analysis was possible (Table 4). For the sub-
population identified in both registers, the concordance increased from 81% in subjects with 
only one hospital discharge, to 87% in subjects with five or more discharges. Corresponding 
concordance for the sub-population in the Patient Register only increased from 50% only in 
subjects with one hospital discharge to 68% in subjects with five or more such discharges. 
Approximately 80% of all study subjects died within the first year of cancer diagnosis (Figure 
2). The probability of survival in the sub-population reported to both the Cancer Register and 
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the Patient Register was higher compared to the sub-populations reported to only one of the 
two registers, but decreased over time.  
Table 4. The concordance between biliary tract cancer diagnosis in the Swedish Cancer 
Register, the Swedish Patient Register, and the Causes of Death Register, stratified by number 
of hospital discharges with a biliary tract cancer diagnosis between 1990 and 2010. 
Sub-population Total Dead Death in biiary tract cancer 
PR-not-CR (%) 6,303 5,833 (93) 3,438 (59) 
   Number of hospital discharges with biliary tract cancer diagnosis (%)  
1 3,020 2,755 1,391 (50) 
2 1,252 1,181 751 (64) 
3 652 622 419 (67) 
4 355 335 238 (71) 
   ≥5 1,024 940 639 (68) 
CR-not-PR (%) 1,171 1,082 (93) 552 (51) 
CR-and-PR (%) 6,799 6,359 (93) 5,358 (84) 
   Number of hospital discharges with  biliary tract cancer diagnosis (%)  
1 2,106 2,009 1,620 (81) 
2 1,274 1,200 1,019 (85) 
3 875 834 714 (86) 
4 555 513 442 (86) 
   ≥5 1,989 1,803 1,563 (87) 
PR-not-CR: Cases in the Patient Register only. CR-and-PR: Cases in both registers. CR-not-PR: Cases in the 
Cancer Register only. 
 
 
 
Figure 2. Survival probability of biliary tract cancer cases registered in the Cancer Register 
(CR) and the Patient Register (PR). CR-and-PR: Cases in both registers. PR-not-CR: Cases in 
the Patient Register only. CR-not-PR: Cases in the Cancer Register only. 
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9.2 STUDY II 
9.2.1 Study subjects 
A total of 21,350 cases of biliary tract cancer were identified in the Cancer Register between 
1970 and 2010 (Table 5). Correspondingly, 24,769 cases were identified in the Causes of 
Death Register. In the Patient Register, 16,505 biliary tract cancer cases were identified 
between 1987 and 2010, of which 2,593 were diagnosed before 1990. Gallbladder cancer was 
the most common sub-site in all three registers (66%, 62% and 56% in the Cancer Register, 
the Patient Register and the Causes of Death Register respectively). The total number of 
biliary tract cancers in the Patient Register differed from that in Study I, because of the 
inclusion of other time periods. Almost 7% of study subjects in the Patient Register were 
diagnosed with biliary tract cancer of multiple sub-sites. 
Table 5. Distribution of patients with biliary tract cancer diagnosis in the Cancer 
Register, the Patient Register, and the Causes of Death Register between 1970 and 
2010. 
  
Cancer Register 
(%) 
Patient Register  
(%)α 
Causes of Death 
Register (%) 
Total 21,350 (100) 16,505 (100) 24,769 (100) 
Gallbladder cancer 14,181 (66) 10,233 (62) 13,963 (56) 
Sex       
Male 6,950 (33) 6,107 (37) 7,983 (32) 
Female 14,400 (67) 10,398 (63) 16,786 (68) 
Age       
0-49 745 (3) 641 (4) 666 (3) 
50-54 733 (3) 592 (4) 684 (3) 
55-59 1,291 (6) 1,021 (6) 1,263 (5) 
60-64 2,083 (10) 1,554 (9) 2,094 (8) 
65-69 2,869 (13) 2,128 (13) 3,108 (13) 
70-74 3,692 (17) 2,604 (16) 4,125 (17) 
75-79 4,010 (19) 3,018 (18) 4,698 (19) 
80+ 5,927 (28) 4,947 (30) 8,131 (33) 
Time period       
1970-1974 2,913 (13) . 2,399 (10) 
1975-1979 3,268 (15) . 2,886 (12) 
1980-1984 3,577 (17) . 3,476 (14) 
1985-1989 3,311 (16) 2,593 (16)β 3,597 (15) 
1990-1994 2,515 (13) 2,989 (18) 3,288 (13) 
1995-1999 2,030 (9) 3,161 (19) 3,054 (12) 
2000-2004 1,804 (8) 3,413 (21) 2,870 (12) 
2005-2010 1,932 (9) 4,349 (26) 3,199 (13) 
α 1987-2010, β 1987-1989     
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9.2.2 The Cancer Register 
Overall, the incidence of biliary tract cancers decreased over time in both men and women 
(Figures 3 and 4). The annual incidence rate among men peaked at almost 8 new 
cases/100,000 persons in the mid 1980’s, where after the incidence rate decreased by 4.2% 
annually (95% CI -4.8 to -3.6) until the end of the study period. In women, the incidence rate 
was stable (APC 0.2, 95% CI -1.1 to 1.5) between 1970 and 1983. After 1983 however, the 
incidence patterns were similar to those seen in men (APC -4.7, 95% CI -5.2 to -4.2). 
In the gallbladder cancer specific analyses, the results were similar to the analyses of biliary 
tract cancer in total, but the decreasing incidence trends starting in the mid 1980’s were 
perhaps more pronounced (APC -6.1, 95% CI -6.8 to -5.3 for men and APC -5.3, 95% CI -5.9 
to -4.8 for women) (Figures 5 and 6). 
 
Figure 3. Standardized incidence/mortality rates of  
biliary tract cancer in men between 1970 and 2010.  
 
Figure 4. Standardized incidence/mortality rates of  
biliary tract cancer in women between 1970 and 2010.  
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At the start of the study period, most biliary tract cancer diagnoses were based on autopsy 
findings in both sexes (Figures 7 and 8). However, the number of male cases based on 
autopsy reports decreased by 10.0% (95% CI -11.1 to -8.9) annually from 1986 and onwards. 
A similar trend was seen in women (APC -11.1, 95% CI -12.0 to -10.3). In men, the number 
of cases based on histopathology increased by 4.0% (95% CI 1.4 to 6.7) annually between 
1970 and 1983. Correspondingly, a similar finding was seen in women (APC 1.5, 95% CI 0.3 
to 2.7). By 2010, the majority of biliary tract cancer diagnoses were based on histopathology 
in men and women even though a decreasing trend in the use of histopathology was seen 
from 1990 onwards. 
 
Figure 5. Standardized incidence/mortality rates of  
gallbladder cancer in men between 1970 and 2010.  
 
Figure 6. Standardized incidence/mortality rates of  
gallbladder cancer in women between 1970 and 2010.  
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Figure 7. Foundation of biliary tract cancer diagnosis reported  
in the Cancer Register in men between 1970 and 2010.   
 
Figure 8. Foundation of biliary tract cancer diagnosis reported  
in the Cancer Register in women between 1970 and 2010.   
 
9.2.3 The Patient Register 
The incidence rate of biliary tract cancer assessed from the Patient Register was stable over 
the study period in men (APC 0.1, 95% CI -0.8 to 0.9). In women, a slightly decreasing trend 
of borderline significance was noted (APC -0.9, 95% CI -1.6 to -0.1).  
For gallbladder cancer specifically, the rate in men decreased by 2.4% (95% CI -3.3 to -1.4) 
annually between 1990 and 2010, but the curve flattened out towards the end of the study 
period. In women, a decreasing trend between 1990 and 1997 was seen (APC -6.3, 95% CI -
8.4 to -4.6). After 1997 however, the incidence trend was stable (APC -0.9, 95% CI -2.3 to 
0.6).  
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9.2.4 The Causes of Death Register 
The mortality rates of biliary tract cancer in men peaked in 1983, where after a decreasing 
trend was observed (APC -1.8, 95% CI -2.5 to -1.2). In women, the mortality rate was stable 
until 1986 (APC 0.7, 95% CI -0.3 to 1.7), but decreased by 2.4% (95% CI -3.0 to -1.9) 
annually thereafter until 2010. From 1987 onwards, the mortality rate was higher than the 
incidence rate (in the Cancer Register) in both men and women (Figures 3 and 4). 
The mortality rates of gallbladder cancer, specifically, also decreased during the study period 
(Figures 5 and 6). In men, the mortality rate increased up until 1985 (APC 3.1, 95% CI 1.2 to 
5.0) but decreased by 4.8% (95% CI -5.6 to -4.1) annually thereafter. In women, the mortality 
trend was stable before 1985 but decreased by 4.4% (95% CI -5.0 to -3.7) annually thereafter. 
9.3 STUDY III 
9.3.1 Study subjects 
A total of 1,896 biliary tract cancer cases were identified, of which; 1169 cases had 
gallbladder cancer; 432 cases had cancer of the extra-hepatic bile ducts; and 295 cases had 
ampullary cancer. The mean age at diagnosis was approximately 57 years, and diabetes was 
more common in cases than controls. Female cases were more often multiparous (more than 
one child) and younger at the birth of the first child, compared to controls.  
9.3.2 Reproductive factors and gallbladder cancer 
Women with three children or more had increased odds of gallbladder cancer (OR 2.06, 95% 
CI 1.68 to 2.51) compared to women with one child (Table 6). Furthermore, the odds of 
gallbladder cancer decreased with increasing age at the birth of the first child in women (OR 
0.54, 95% CI 0.41 to 0.70).  
The association between parity and gallbladder cancer was unchanged in women aged 50 
years or more at diagnosis (OR 2.34, 95% CI 1.87 to 2.93 for women with ≥3 children), 
whereas no association was seen in women aged less than 50 years (Table 7). The association 
between a woman’s age at the first birth and gallbladder cancer was unchanged by 
stratification for age at diagnosis. 
There was a positive association between increasing number of children and gallbladder 
cancer in men (OR 1.70, 95% CI 1.20 to 2.40 for men with ≥3 children). However, no 
association between age at the birth of the first child and gallbladder cancer was observed. 
The association between number of children and gallbladder cancer remained in men aged 50 
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years or more at diagnosis and no association was seen in men aged less than 50 at diagnosis 
(data not shown). 
 
9.3.3 Reproductive factors and cancers of the extra-hepatic bile ducts and the Ampulla 
Women and men with three or more children had increased odds of cancer of the extra-
hepatic bile ducts (OR 1.65, 95% CI 1.07 to 2.55 for women and OR 2.57, 95% CI 1.65 to 
3.98 for men). Similar associations were observed for Ampullary cancers (OR 1.56, 95% CI 
0.89 to 2.73 for women and OR 2.77, 95% CI 1.61 to 4.77 for men). Furthermore, there was 
an inverse association between age at the birth of the first child and cancer of the extra-
hepatic bile duct, but the results were generally similar in men and women (Table 6). Women 
Table 6. The association between reproductive factors and biliary tract cancer in 
men and women, expressed as adjusted odds ratios (OR) with 95% confidence 
intervals (CI) by sub-site. 
		 Gallbladder cancer Cancers of the extra-hepatic bile ducts Ampullary cancer 		 OR (95 % CI)α OR (95 % CI)α OR (95 % CI)α 
Women 		 		 		
Number of children 		 		 		
0 1.00 (0.76 - 1.32) 1.40 (0.84 - 2.33) 0.47 (0.20 - 1.13) 
1 Reference Reference Reference 
2 1.59 (1.30 - 1.94) 1.64 (1.09 - 2.46) 1.51 (0.88 - 2.60) 
≥3 2.06 (1.68 - 2.51) 1.65 (1.07 - 2.55) 1.56 (0.89 - 2.73) 
Age at the birth of the first child (years) 		 		
≤22 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
23-29 0.71 (0.60 - 0.83) 0.60 (0.43 - 0.84) 0.97 (0.61 - 1.53) 
≥30 0.54 (0.41 - 0.70) 0.61 (0.36 - 1.04) 0.86 (0.45 - 1.64) 
Men 		 		 		
Number of children 		 		 		
0 1.26 (0.85 - 1.87) 1.87 (1.15 - 3.01) 2.42 (1.39 - 4.23) 
1 Reference Reference Reference 
2 1.43 (1.01 - 2.01) 1.78 (1.16 - 2.73) 3.32 (1.98 - 5.54) 
≥3 1.70 (1.20 - 2.40) 2.57 (1.65 - 3.98) 2.77 (1.61 - 4.77) 
Age at the birth of the first child (years) 		 		
≤22 Reference Reference Reference 
23-29 1.03 (0.72 - 1.48) 0.75 (0.50 - 1.11) 0.71 (0.45 - 1.13) 
≥30 1.05 (0.69 - 1.59) 0.67 (0.42 - 1.06) 0.73 (0.44 - 1.23) 
α
 Model is adjusted for diabetes, alcohol use, smoking, birth country and educational level. 
36 
 
and men aged 30 years or more had slightly decreased odds of Ampullary cancer, though the 
associations were not statistically significant. 
Table 7. Association between reproductive factors and gallbladder cancer in women 
stratified for age at diagnosis, expressed as odds ratios (OR) with 95% confidence 
intervals (CI) . 
  <50 years at diagnosis ≥50 years at diagnosis 
  OR (95 % CI) 
α OR (95 % CI) α 
Number of children     
0 1.01 (0.58 - 1.76) 0.99 (0.72 - 1.37) 
1 Reference Reference 
2 1.11 (0.72 - 1.71) 1.72 (1.37 - 2.16) 
≥3 1.16 (0.73 - 1.84) 2.34 (1.87 - 2.93) 
Age at the birth of the first child (years)     
≤22 Reference Reference 
23-29 0.65 (0.46 - 0.94) 0.72 (0.60 -  0.86) 
≥30 0.46 (0.23- 0.90) 0.55 (0.41 - 0.75) 
α
 Model is adjusted for diabetes, alcohol use, smoking, birth country and educational level. 
 
9.4 STUDY IV 
9.4.1 Study subjects 
The study included 203,131 men with prostate cancer, providing 849,307 person-years of 
follow-up time after exclusion of the first year of follow-up. In total, 22.5% (45,744 
individuals) of all study subjects were considered more exposed to estrogen therapy, and the 
remaining 77.5% (157,387 individuals) were considered less exposed. A total of 7,068 
individuals were excluded in the gallbladder cancer-specific analyses because of a history of 
cholecystectomy before the start of the study. The median follow-up time was 3.8 years 
(Inter-quartile range (IQR): 1.6 to 7.2 years).  
9.4.2 Risk of gallbladder cancer 
The median follow-up time was 3.9 years in the more exposed group and 3.2 years in the less 
exposed group. Altogether, 17 gallbladder cancers were observed in the more exposed group, 
compared to the expected 19.5 (SIR 0.87, 95% CI 0.51 to 1.39). Correspondingly, 24 
gallbladder cancers were identified in the less exposed group compared to the expected 29.7 
(SIR 0.81, 95% CI 0.52 to 1.21). In the sensitivity analysis, the point estimates decreased, but 
there were no clear differences between the more exposed and the less exposed groups (Table 
8). A decreased risk of gallbladder cancer was also indicated when the two groups were 
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combined (OR 0.83, 95% 0.60 to 1.13) and was statistically significant in the sensitivity 
analysis excluding cohort members with known risk factors for biliary tract cancer (OR 0.67, 
95% CI 0.44 to 0.97). 
Men in the more exposed group with a latency time of more than five years (prolonged 
exposure) had an increased point estimate of gallbladder cancer, though the association was 
not statistically significant (SIR 1.34, 95% CI 0.71 to 2.29). The stratified analysis did not 
change the results for the less exposed group (Table 8).  
Table 8. Standardized incidence ratios (SIR) with 95% confidence intervals (CI) for 
biliary tract cancer between 1961 and 2008, stratified for latency time. 
		
Number of 
observed cases 
Number of 
expected cases 
Main analysis   
SIR (95% CI) 
Sensitivity analysis 
SIR (95% CI) b 
Gallbladder cancer 
1961-2008 41 49.2 0.83 (0.60-1.13) 0.67 (0.44-0.97) 
1961-1980c 17 19.5 0.87 (0.51-1.39) 0.63 (0.31-1.13) 
>1-5 years 4 9.8 0.41 (0.11-1.04) . 
>5 years 13 9.7 1.34 (0.71-2.29) . 
1981-2008  24 29.7 0.81 (0.52-1.21) 0.69 (0.40-1.11) 
>1-5 years 15 18.4 0.81 (0.46-1.34) . 
>5 years 9 11.3 0.80 (0.36-1.52) . 
Cancers of the extra-hepatic bile ducts a  
1961-2008 36 45.5 0.79 (0.55-1.10) 0.73 (0.48-1.06) 
1961-1980c 13 14.4 0.91 (0.48-1.55) 0.80 (0.39-1.48) 
>1-5 years 4 5.6 0.71 (0.19-1.83) . 
>5 years 9 7.5 1.20 (0.55-2.28) . 
1981-2008  23 31.1 0.74 (0.47-1.11) 0.69 (0.40-1.10) 
>1-5 years 13 15.1 0.86 (0.46-1.47) . 
>5 years 10 12.7 0.78 (0.38-1.44) . 
a Extra-hepatic bile ducts also included Ampullary cancer 
b The anlaysis excluded subjects with: gallstone disease who did not undergo cholecystectomy, diabetes, 
obesity, alcohol abuse or primary sclerosing cholangitis prior to prostate cancer diagnosis. 
c More exposed to oestrogen 
 
9.4.3 Risk of cancers of the extra-hepatic bile ducts and the Ampulla 
The median follow-up time in the more exposed and the less exposed groups was 3.3 and 4.0 
years, respectively. In all, 13 cancers of the extra-hepatic bile ducts were observed in the 
more exposed group, compared to the expected 14.4 (SIR 0.91, 95% CI 0.48 to 1.55). In the 
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less exposed group, 23 cases were observed in contrast to the expected 31.3 (SIR 0.74, 95% 
CI 0.47 to 1.11). There were no major changes in the sensitivity analyses (Table 8). The 
decreased risk estimate remained when the two groups were analyzed together (OR 0.79, 
95% CI 0.55 to 1.10).  
The latency time analyses showed an increased risk of cancer for men in the more exposed 
group with a latency time of more than 5 years, but the association was not statistically 
significant (SIR 1.20, 95% CI 0.55 to 2.28). There were no clear differences in the less 
exposed group between subjects with different latency time.  
9.5 STUDY V 
9.5.1 Study subjects  
The final matched cohort consisted of more than 1.1 million women, of which 290,186 
women were ever exposed to menopausal hormone therapy. A total of 154,198 women were 
treated with combination regimens and 135,988 women were treated with regimens 
containing estrogen only (Table 9). The median duration of hormone treatment was 1.8 years 
(IQR: 0.7-4.3). The median age at inclusion was 57 years (52-66) and the mean follow-up 
time in the exposed and unexposed were 5.6 (Standard deviation[SD]: 2.3) and 7.3 (SD 1.8) 
years, respectively.  
The unmatched cohort included more than 3.6 million unexposed women and the mean 
follow-up time in the unexposed was 7.5 years (SD: 1.2). The total follow-up time was 
27,009,996 person-years.  
 
 
 
 
 
 
 
 
39 
 
Table 9. Characteristics of exposed and unexposed individuals in Study V. 
Variable 
Exposed 
subjects 
Unexposed subjects 
(matched cohort) 
Unexposed subjects 
(unmatched cohort) 
Total (%) 290,186 (100) 870,165 (100) 3,625,136 (100) 
Matching and/or confounding variables (%) 
Delivery 117,861 (40.6) 353,282 (40.6) . 
Thrombotic events 40,316 (13.9) 120,931 (13.9) . 
Hysterectomy 51,811 (17.9) 155,138 (17.8) 237,380 (6.7) 
Diabetes 15,936 (5.5) 48,422 (5.6) 69,607 (2.0) 
Obesity 5,146 (1.8) 15,526 (1.8) . 
Smoking-related disease 13,601 (4.7) 40,994 (4.7) . 
Alcohol abuse 7,293 (2.5) 21,455 (2.5) . 
Osteoporosis 8,256 (2.9) 22,764 (2.6) . 
Cholecystectomy  25,553 (8.6) 49,818 (5.7) 176,444 (4.9) 
Gallstone disease 29,102 (10.0) 79,933 (9.2) 245,581 (6.8) 
Type of hormonal regimen (%)     
Estrogen only 135,988 (46.9) . . 
Esotrogen/progestin 
combination 154,198 (53.1) . . 
 
9.5.2 Menopausal hormone therapy and gallbladder cancer 
In the matched cohort, a total of 47 and 168 gallbladder cancers were identified in the 
exposed and the unexposed group, respectively. There was an inverse association between 
menopausal hormone therapy and gallbladder cancer, however the finding was not 
statistically significant (OR 0.84, 95% CI 0.60 to 1.15). The OR for combination regimens 
was 0.73 (95% CI 0.43 to 1.23), and 0.91 (95% CI 0.62 to 1.35) for regimens containing only 
estrogen.  
In the unmatched cohort, a total of 714 gallbladder cancers were identified in the unexposed 
group. The associations between menopausal hormone therapy and gallbladder cancer were 
similar to those observed in the matched cohort (Table 10). 
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Table 10. Menopausal hormone therapy (MHT) and risk of biliary tract cancer 
by subsite, expressed as odds ratios (OR) α with 95 % confidence intervals 
(CI) or hazard ratios (HR) β and 95% CI. 
Matched cohort 
  All MHT Estrogen only 
Estrogen and 
progestin 
combination 
		 OR (95 % CI) OR (95 % CI) OR (95 % CI) 
Gallbladder cancer 0.84 (0.60 - 1.15) 0.91 (0.62 - 1.35) 0.73 (0.43 - 1.23) 
Cancer of the extra-
hepatic bile duct and 
the Ampulla 
0.83 (0.61 - 1.15) 0.74 (0.48 - 1.14) 0.97 (0.63 - 1.51) 
Gallstone disease 6.95 (6.64 - 7.28) 7.18 (6.79 – 7.59) 6.83 (6.47 – 7.21) 
Unmatched cohort 
  
All MHT Estrogen only 
Estrogen and 
progestin 
combination 
  HR (95% CI) HR (95% CI) HR (95% CI) 
Gallbladder cancer 0.88 (0.69-1.13) 0.94 (0.64-1.40) 0.84 (0.61-1.15) 
Cancers of the extra-
hepatic bile ducts and 
the Ampulla 
1.02 (0.76-1.37) 0.94 (0.64-1.38) 1.16 (0.76-1.77) 
              α Adjusted for the matching variables and osteoporosis. 
              β Adjusted for age, diabetes, primary sclerosing cholangitis, hysterectomy and gallstone disease.  
9.5.3 Menopausal hormone therapy and cancers of the extra-hepatic bile ducts  
A total of 48 cancers of the extra-hepatic bile ducts were identified in the exposed group. The 
corresponding number in the unexposed group was 174. There was no clear association with 
menopausal hormone therapy (OR 0.83, 95% CI 0.61 to 1.15). In women exposed to 
combination regimens, the OR was 0.97 (95% CI 0.63 to 1.51), whereas the OR was 0.74 
(95% CI 0.49 to 1.14) in women exposed to regimens containing estrogen only.  
A total of 428 cancers of the extra-hepatic bile duct or Ampulla were identified among the 
unexposed in the unmatched cohort. The slightly decreased risk of cancer observed in the 
matched cohort was attenuated in the unmatched cohort (HR 1.02, 95% CI 0.76 to 1.37). 
However, there were no statistically significant results in either cohort (Table 10).  
9.5.4 Menopausal hormone therapy and gallstone disease 
In the matched cohort, there was a positive association between menopausal hormone therapy 
and gallstone disease in women without a history of gallstones prior to exposure to hormone 
therapy (OR 6.95, 95% CI 6.64 to 7.28). 
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10 METHODOLOGICAL CONSIDERATIONS 
10.1 STUDY DESIGN 
Most research may be readily categorized as either experimental or observational. One may 
consider the difference between the two by the way the study participants receive the 
exposure of interest. In the experimental setting, the researcher imposes the exposure 
(intervention) on the study participant, much like in any other kind of experiment. Whereas in 
the observational setting, the researcher simply observes the exposure, without influencing 
the form of exposure or even the decision to actually expose any subject. In the modern 
evidence-based world of medicine, the experimental design is favored because of the 
possibility to use randomization in order to achieve a “confounding-free” study. However, 
many exposures are not suitable for the experimental study design because of ethical or 
practical considerations. For example, random allocation of parity or menopausal hormone 
therapy (Studies III and V respectively) is not feasible, and randomization of prostate cancer 
treatment to study biliary tract cancer (Study IV) is impossible. Furthermore, all types of 
study design have strengths and weaknesses which must be considered before choosing the 
most appropriate design for the research question. The most common types of observational 
designs are the cohort design, the case-control design, the cross-sectional design and the 
ecological design. Studies I, II, IV and V are examples of cohort studies, while Study III was 
a case-control study. 
In cohort studies, the study subjects are categorized according to exposure status (exposed vs 
unexposed) and followed over time for an outcome (biliary tract cancer for example). It is 
desired that the exposed and the unexposed individuals are as alike as possible in every 
aspect, except for the exposure variable. Study V included a matched cohort using a rather 
extensive matching procedure similar to a propensity score matching procedure. The purpose 
of such a procedure is to make the groups (exposed and unexposed) as similar as possible to 
mimic the effect of a randomization.(177) Therefore, factors not necessarily associated with 
both exposure and outcome were included in the matching procedure to capture influence 
from unmeasured factors by making exposed and unexposed individuals as alike as possible. 
Cohort studies are generally regarded superior to other observational designs in the hierarchy 
of evidence. The cohort design is effective when more than one exposure is to be investigated 
and the outcome is not too rare.  
In the case-control design, the study subjects are instead grouped by their outcome status, as 
cases and not cases. Control subjects are then selected from the “not case” group for 
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comparison with the cases. The exposure status is then collected for the both the cases and 
controls, making case-control studies essentially retrospective in nature. Thus, one may 
consider that the case-control study actually investigates the likelihood of being exposed 
depending on outcome status. The case-control design is efficient when the outcome is rare 
because the cost and effort needed to collect a reasonable sample size may be kept at 
minimum. However, great care must be taken in the sampling of controls. It is important that 
the control group accurately reflects the prevalence of the exposure in the population from 
which the cases were identified to avoid selection bias, which may otherwise severely limit 
the value of a case-control study. Furthermore, the manner in which the controls are sampled 
is of importance. Also, the number of controls per case must be considered because the 
optimal ratio may vary depending on the study parameters and research question. In Study 
III, 10 controls per case were selected from the same source population that was used to 
identify the cases, at random at the time the corresponding case was classified as a case. This 
type of sampling is referred to as density-based sampling. A smaller number of controls (e.g. 
5 per case) could have been used without compromising statistical power much. 
10.2 VALIDITY 
10.2.1 Internal validity 
The results of an internally valid study accurately reflect what the study was meant to reflect. 
That is, the study measures what it was intended to measure. A study lacking internal validity 
may be flawed or poorly performed in such a way that the results of the study are dubious or 
even incorrect and is therefore a major concern for the inference of the study. Error in a study 
will affect the internal validity and may be introduced on many levels. 
10.2.2 External validity 
The extent to which the inference of a study may be extrapolated to other populations than 
the study population, or in other words, the generalizability, is often termed external validity. 
With this in mind, external validity is not normally calculated or estimated, (nor is internal, 
for that matter) but is more an analysis of thought based on aspects such as study design. 
Generally, the external validity does not impose limits in the actual results of the study, only 
the generalizability. However, for a study to be generalizable, a good internal validity is 
necessary. All studies included in this thesis are population-based, which is one method that 
may be used to improve the external validity of any study.  
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10.3 ERROR 
10.3.1 Random error 
The precision of a study is inversely correlated with the degree of random error. Random 
error, as the term implies, will not drive results in a specific direction but rather gives rise to a 
less precise estimate. The level of random error can be estimated using hypothesis testing and 
is most often expressed as a confidence interval or a p-value related to the null-hypothesis. 
The null hypothesis is often the opposite of the research question, perhaps that there is no 
association between exposure and outcome. In Studies II-V, a 95% CI indicated an interval in 
which the estimate would be found, 95% of the times, if the study where to be repeated under 
the exact same conditions. Analogously, the p-value is the probability that the observed 
difference, or greater, between two groups is based solely on chance if the null-hypothesis is 
actually true. Hypothesis testing aims to either reject or accept the null hypothesis. 
Consequently, the null-hypothesis may be rejected even though it is true, referred to as Type-
I error. That is, an association between two variables may be observed even though there is 
none. Furthermore, the null-hypothesis may be accepted even though it is false, which is 
referred to as Type-II error. That is, no association between two variables is observed, even 
though there actually is one. To minimize random error in this thesis, predefined hypotheses 
were used to reduce multiple testing. Also, exposures and outcomes were clearly defined and 
the population-based design entailed the inclusion of the entire Swedish population as the 
source population to increase sample size. Studies II-V, all used 95% CI to assess the level of 
present random error. 
10.3.2 Systematic error (bias) 
Contrary to random error, systematic error skew the results in a specific direction and is also 
called bias. In theory, a randomized experimental study should be the best way of limiting the 
influence of bias. Bias can be categorized, but always represents a major concern for the 
validity of any observational study, regardless of the type of bias. 
Selection bias is the result of a systematically incorrect or invalid sampling of subjects so that 
the groups under study differ systematically. Even though selection bias is mostly just a 
potential issue in case-control studies, cohort studies can also be hampered by an incorrect 
sampling of unexposed subjects. In cohort studies, selection bias may occur e.g. if the loss of 
follow-up is different in the exposed and unexposed group. To minimize selection bias in 
Study III, the controls were sampled in a random fashion, and from the same population-
based source population from which the cases were derived. The follow-up in all studies 
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included in this thesis was register-based, which counteracts selection bias due to loss of 
follow-up.  
Information bias, or misclassification, is the result of inaccuracies or errors in the 
classification/measurement of a variable. In register-based research, the correctness of 
diagnosis codes used for categorizing a variable is a common source of misclassification. For 
example, routines in coding may differ between practitioners and some diseases may be more 
easily identified and coded, introducing misclassification. In some settings, the 
misclassification of a variable may differ between groups in the study, termed differential 
misclassification, and may skew the results of the study in either direction. However, if the 
error is similar between groups, a non-differential (random) misclassification is present, 
resulting in an estimate skewed towards null. It is possible that some non-differential 
misclassification is present in the studies of this thesis due to the register-based design. The 
classification of the exposure and confounding variables in Studies III-V may be subjected to 
non-differential misclassification. The categorization of the outcome in Studies III-V was 
based on the Cancer Register, which should limit the effect of misclassification of the 
outcome due to the high quality of the data in the register. Misclassification as a result of 
coding errors in the registers is likely not dependent on the exposure and outcome in Studies 
III-V, and should thus only introduce non-differential misclassification, if any. The exposure 
variable in Study IV, prostate cancer, was used as a proxy for exogenous hormone exposure. 
A proxy was used out of necessity because actual sex hormone exposure information 
(hormones administered to the patient) was not available for analysis. This is a limitation of 
Study IV and should be considered. However, the rationale behind the use of prostate cancer 
as a proxy for hormone exposure in men is scientifically sound. 
In many settings, a separate factor, associated with both exposure and outcome, may 
influence the result of a study. This type of bias is labeled confounding. If this separate factor 
is not within the causal pathway between exposure and outcome, the factor can distort or 
confound the association. Confounding may be examined using Directed Acyclic Graphs 
(DAG), in which a diagram of the factors of interest are visualized.(178) In this thesis, the 
inclusion of important confounding factors such as age, sex, primary sclerosing cholangitis, 
educational level and diabetes, as covariates in the multivariable analyses of Studies III and V 
should limit the effect of cofounding on the observed associations. Furthermore, the use of 
sensitivity analyses in Study IV allowed for quantification of the confounding effect. 
Gallstone disease is an important risk factor for biliary tract cancer. Furthermore, gallstone 
disease may be associated with the exposures in Studies III (parity) and V (menopausal 
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hormone therapy). However, because gallstone disease is an intermediary step between 
exposure (parity) and outcome (biliary tract cancer), it may be considered a mediator rather 
than a confounding factor. Adjustment for a mediating factor (gallstone disease) will affect 
the strength of the association between exposure and outcome, and the effect size corresponds 
to the strength of the pathway through the mediator. However, if the goal is to assess the 
association without the pathway of the mediator, adjustment for the mediating factors can be 
performed. Despite efforts to reduce the effect of confounding in this thesis, a residual effect 
of lifestyle factors, such as obesity and other unmeasured factors is possible. 
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11 GENERAL DISCUSSION 
11.1 STUDY I – UNDER-REPORTING OF BILIARY TRACT CANCER  
There is substantial under-reporting of biliary tract cancer to the Cancer Register, i.e. 44% of 
cases diagnosed with biliary tract cancer are not reported. The rate of non-reporting is higher 
in the elderly and in cases diagnosed in more recent time periods. The proportion of cases 
with unreported (to the Cancer Register) biliary tract cancer more often have a non-biliary 
tract cancer as the cause of death compared to reported cases. Furthermore, the clear majority 
of biliary tract cancer cases die within one year of diagnosis and the survival is best for cases 
identified in both the Cancer Register and the Patient Register.  
The reason for the under-reporting is not entirely understood. The change in diagnostic tools 
available for diagnosing biliary tract cancer may play a role, however. Cancer diagnoses in 
elderly patients with advanced disease are often based on radiology only.(179) This could be 
an explanation for the finding that elderly patients and those diagnosed in a later time period 
are less likely to be reported to the Cancer Register. Some previous studies have 
demonstrated under-reporting of other cancers to the Cancer Register, but no previous study 
has investigated biliary tract cancer specifically.(7, 180)  
Biliary tract cancer is less often reported as the cause of death in unreported compared to 
reported cases. Furthermore, the concordance between the Cancer Register/Patient Register 
and the Causes of Death Register increased with the number of hospital discharges. These 
findings suggest that misclassification of biliary tract cancer in the Patient Register could be 
more common in the unreported. Such a misclassification could lead to an overestimation of 
the under-reporting to the Cancer Register because of a potentially incorrect biliary tract 
cancer diagnosis in the Patient Register. However, it is unlikely that misclassification fully 
explains the relatively large differences between the registers.  
The better survival for cases reported to the Cancer Register and the Patient Register is likely 
an effect of the selection of patients reported to the Cancer Register, e.g., the elderly may less 
often be suited to a curative treatment, which will greatly affect survival. (5) 
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11.2 STUDY II – THE INCIDENCE OF BILIARY TRACT CANCER 
The incidence of biliary tact cancer, especially gallbladder cancer, has decreased from 1970 
until 2010. However, in comparing the Cancer Register with the Patient Register and the 
Causes of Death Register, an overestimation of the decreasing trends is likely.  
The incidence of biliary tract cancer based on the Cancer Register reveals decreasing trends 
from the mid 1980’s onwards. The trend is particularly strong in gallbladder cancer; a 
decrease of approximately 75% from 1985 to 2010 was observed in both men and women. 
Similar developments have been reported from other parts of Europe.(112, 115) Furthermore, 
accounts based on data from the US have shown analogous findings.(107-109) However, 
some studies have shown a more stable trend of cancers of the extra-hepatic bile ducts 
specifically, but the findings have been contradictory.(112-114)  
The reasons behind the decreasing incidence trends are unclear. There has been no dramatic 
elimination of the few risk factors identified for biliary tract cancer to explain these findings. 
The increasing use of cholecystectomy with the advent of the laparoscopic approach has been 
suggested as an explanation, but available research has failed to substantiate that 
argument.(181) Moreover, obesity and diabetes, both risk factors for biliary tract cancer, have 
rather increased world-wide.(182, 183) Furthermore, the increasing age in the population 
should increase the incidence also in rare tumors such as biliary tract cancer.(184)  
The more stable trend found in the Patient Register, suggests that under-reporting of biliary 
tract cancer to the Cancer Register may obscure the actual incidence trends. The first study of 
this thesis showed that under-reporting increased with time period. Such a situation could 
explain the decreasing incidence trends observed in Study II, at least in part. Although these 
results could be explained by misclassification of biliary tract cancer in the Patient Register, it 
is unlikely that such misclassification has increased with time to fully explain the observed 
findings. 
Furthermore, the mortality rate of biliary tract cancer decreased less markedly and was higher 
than the incidence rate based on the Cancer Register during the second half of the study 
period. This finding further supports the impression that progressively increasing under-
reporting to the Cancer Register is a likely explanation, at least in part, for the otherwise 
mysteriously decreasing incidence trends of biliary tract cancer in Sweden.  
 
 
48 
 
11.3 STUDY III – REPRODUCTIVE FACTORS AND BILIARY TRACT CANCER 
Study III did not find evidence to support a role of reproductive factors in the etiology of 
biliary tract cancer as a whole. However, for gallbladder cancer specifically, the hormonal 
hypothesis could not be completely rejected. For cancers of the extra-hepatic bile ducts and 
ampullary cancers, the odds of biliary tract cancer increased with increasing number of 
children and decreased with increasing age at the birth of the first child. However, the 
associations between the exposures and biliary tract cancer were similar in men and women 
suggesting an effect of unmeasured confounding rather than a biological effect. For example, 
parity has been correlated with obesity in women.(185) A limited body of evidence suggests 
that paternal weight gain may also occur during pregnancy, but large systematic studies are 
lacking.(186) The analyses were adjusted for educational level but no adjustment for obesity 
was possible. Life style factors, such as obesity, could explain the similar findings in men and 
women. A hormonal explanation to the findings seems implausible. 
Concerning gallbladder cancer specifically, there was a positive association between parity 
and cancer, but only in post-menopausal (aged >50 years at cancer diagnosis) women. There 
was no clear association between parity and gallbladder cancer in pre-menopausal women. 
Furthermore, an inverse association between increasing age at the birth of the first child and 
cancer risk in women was seen. In men, the odds of gallbladder cancer also increased with 
increasing parity, though, the age-stratified analysis revealed that the effect was restricted to 
men aged 50 years or more. However, a man’s age at the birth of the first child did not affect 
the odds of gallbladder cancer however. A potential effect of sex hormone exposure in 
gallbladder cancer etiology cannot be excluded, yet, the results presented herein do not 
strongly support the hormonal hypothesis. 
To the authors’ knowledge, this is the first study to examine the association between 
reproductive factors and biliary tract cancer and include men in the analyses as an extra level 
of control. Available literature suggests an association between reproductive factors and 
gallbladder cancer in women.(70, 142, 146, 147) However, these studies did not include men 
as a global control group. Furthermore, the findings in the present study underline the 
importance of differentiating gallbladder cancer from other biliary tract cancers in etiological 
research using sex hormones as the exposure.  
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11.4 STUDY IV – EXOGENOUS ESTROGEN AND BILIARY TRACT CANCER IN 
MEN 
Estrogen exposure in men may not be an important risk factor for biliary tract cancer. The 
results of Study IV showed a decreased risk of biliary tract cancer in prostate cancer patients. 
To the author’s knowledge, this study is the first to evaluate if exogenous hormone exposure 
in men may affect the risk of biliary tract cancer. However, an inverse association between 
prostate cancer and biliary tract cancer has been reported previously.(187)  
The explanation to this finding is interesting, but elusive. The first year of follow-up was 
excluded to account for potential surveillance bias. Also, though under-reporting of biliary 
tract cancer is time dependent, any such misclassification should be non-differential because 
the background population from the same time period was used as comparison. The 
sensitivity analyses showed a somewhat further reduced risk of biliary tract cancer when 
subjects with known risk factors were excluded. This observation suggests an influence of 
confounding in the analyses, but the association was rather modest and does not explain the 
decreased risk of cancer that was observed.  
In subjects with prolonged exposure (time between prostate cancer and biliary tract cancer), 
the risk of biliary tract cancer was increased in the more exposed group, however, the 
association was weak. In the less exposed group though, there were no latency time-
dependent differences. A prolonged hormone exposure in men could potentially contribute to 
a carcinogenic process in the biliary tract. Nevertheless, further research is needed to 
investigate this hypothesis and to address the potentially protective effect of exogenous 
hormone exposure in male biliary tract cancer. 
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11.5 STUDY V – MENOPAUSAL HORMONE THERAPY AND BILIARY TRACT 
CANCER  
Study V did not show any clear association between menopausal hormone therapy and biliary 
tract cancer and there was no clear difference between hormone regimens. Yet, a non-
significant, protective effect against gallbladder cancer was suggested. In addition, the study 
could confirm the previously reported increased risk of gallstone disease in women exposed 
to menopausal hormone therapy.  
Some previous studies have reported a positive association between menopausal hormone 
therapy and biliary tract cancer, whereas others have found opposite results. However, the 
studies that indicated an increased risk did not adjust for gallstone disease and it is unclear 
how cholecystectomy was handled in the studies. (149, 150) It is possible that gallstone 
disease influenced the results in those studies. One study, where adjustment for gallstone 
disease was performed, indicated a borderline reduced risk of gallbladder cancer specifically, 
similar to what was seen in this study.(145) Some of the older studies did not differentiate 
between biliary tract and liver cancer, making comparison to the present study 
inappropriate.(151, 153)  
Study V adjusted for some potentially important confounding factors such as age, diabetes, 
and prior hysterectomy. Furthermore, the study was analyzed using two different approaches 
and the results were similar, strengthening the reliability of the observations. The matched 
cohort was constructed in an effort to account for unmeasured factors, such as dietary patterns 
and other lifestyle factors, that may be similar in women with other similarities. The 
unmatched approach using survival analyses was employed in parallel to verify the observed 
associations.  
Gallstone disease was accounted for to assess any influence of menopausal hormone therapy 
on the risk of biliary tract cancer without the gallstone mediated pathway. The increased risk 
of gallstone disease in women exposed to hormone therapy is well documented.(135) 
Furthermore, obesity is also associated with gallstone disease.(188) However, obesity may 
also be more prevalent in women using menopausal hormones compared to women who do 
not.(189) Even though the matched cohort design was employed to address an influence of 
unmeasured potentially confounding factors, the study may not reliably account for life style 
factors such as obesity, dietary pattern etc. and residual confounding cannot, therefore, be 
completely ruled out. Based on the results of the present study and the results of the previous 
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literature, there is insufficient data to support the hypothesis that menopausal hormone 
therapy increases the risk of biliary tract cancer.   
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12 CONCLUSIONS 
 
• A substantial proportion of biliary tract cancers are not reported to the Swedish 
Cancer Register. The under-reporting increases with increasing patient age and later 
time period.  
 
• The decreasing incidence trend of biliary tract cancer in Sweden is likely over-
estimated.  
 
• Reproductive factors are associated with biliary tract cancer in both women and men 
and a hormonal mechanism in biliary tract cancer is thus not supported. A role of sex 
hormone exposure in gallbladder cancer etiology specifically cannot be ruled out.  
 
• Men with prostate cancer might have a generally decreased risk of biliary tract cancer, 
but any potential risk increase in indivuduals with prolonged estrogen exposure seems 
to be small. Further reserach is needed to investigate a protective effect of estrogen 
exposure on the development of biliary tract cancer in men.  
 
• Menopasusal hormone therapy does not seem to increase the risk of biliary tract 
cancer in women.  
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13 FUTURE RESEARCH 
The incidence and time trends of any cancer are important to correctly understand the disease 
and to help guide future research. Furthermore, the robustness of academic research based on 
a register will always depend on the quality of the data. There is a great need to evaluate the 
Swedish health-care registers from a disease-specific point of view. This thesis shows that the 
elderly are less likely to be included in the Cancer Register. This raises the question as to 
whether this applies to other cancers as well and to what extent? One other interesting 
research question would be if there are differences in the rate of reporting depending on 
geography or type of health-care provider diagnosing the cancer. In biliary tract cancer 
specifically, an investigation into the correctness of diagnoses in the Patient Register would 
be of interest to understand to what extent the reported incidence rates are under-estimated.  
Concerning sex hormones and the risk of developing biliary tract cancer, there is a need for 
further investigations. The need to adequately distinguish between gallbladder cancer and 
other extra-hepatic lesions is clear, however. One general difficulty in studying endogenous 
sex hormones as an exposure is to assess the exposure over time. Future research should 
focus on how to better measure cumulative estrogen exposure over time and then use that 
information to investigate the risk of biliary tract cancer further. Additionally, to approach the 
problem from another angle, investigations of biliary tract cancer risk in hormone deficient 
subjects such as women subjected to oophorectomy/hysterectomy (removal of the 
ovaries/uterus) are rare and population-based studies may shed some light on the problem.  
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14 POPULÄRVETENSKAPLIG SAMMANFATTNING 
14.1 Bakgrund 
Gallvägscancer utanför levern är en cancerform med mycket dålig prognos och hög 
dödlighet. Det är en generellt ovanlig tumörform och drabbar ungefär 350 personer per år i 
Sverige. I Sverige beräknar vi cancerförekomst genom det svenska Cancerregistret, dit alla 
läkare som diagnosticerar cancer har en skyldighet att rapportera nyupptäckta fall. De senaste 
åren har man noterat att antalet nyinsjuknade i gallvägscancer sjunker. Patienter som får 
gallvägscancer märker som regel inte av något specifikt symtom, vilket också gör diagnosen 
svår. De flesta patienter söker vård först när tumören har spridit sig lokalt eller till andra delar 
av kroppen vilket medför att bot i princip inte är möjlig. De vanligaste symtomen är trötthet, 
viktnedgång, illamående och buksmärta. Gulsot kan tillstöta om gallvägen stängs av helt. Den 
enda botande behandlingen är en operation där man tar bort all cancervävnad. Ingreppet är 
ofta omfattande och bara ca 25 % av patienterna som får gallvägscancerdiagnos lämpar sig 
för operation. Orsakerna till att man får gallvägscancer är inte helt kända, men man vet att en 
andel av tumörerna (gallblåsecancer) är betydligt vanligare bland kvinnor. Denna avhandling 
syftar till att utreda om förekomsten av gallvägscancer verkligen minskar samt om kvinnliga 
könshormoner påverkar risken att utveckla gallvägscancer.  
14.2 Metoder och resultat 
Rapporter från de sista årtiondena har visat att gallvägscancer blir allt mindre vanligt. Syftet 
med Studie I och Studie II var att undersöka om patienter med gallvägscancer verkligen 
rapporteras till det svenska Cancerregistret och att beräkna nyinsjuknandet och dödligheten i 
gallvägscancer. Studierna baserades på data från de stora folkhälsoregistren: Cancerregistret, 
Patientregistret och Dödsorsaksregistret mellan 1990 och 2010. Registren jämfördes med 
varandra för att se om de patienter som vårdats för gallvägscancer rapporterats till 
Cancerregistret och om dödsorsaken också stämde. Knappt hälften (44 %) av alla patienter 
som vårdats för gallvägscancer rapporterades inte till Cancerregistret. Vidare blev andelen 
som rapporterades till Cancerregistret än mindre med stigande patientålder och under senare 
tidsperioder. Dödligheten för patienter som inte rapporterats till Cancerregistret var också 
sämre än för de patienter som fanns med i Cancerregistret. Studie II visade att nyinsjuknandet 
i gallvägscancer förmodligen minskar i Sverige från 1980-talet och framåt, men att den 
kraftiga nedgång som tidigare rapporterats är överdriven. Dödligheten i gallvägscancer har 
också minskat, men inte i den utsträckning nyinsjuknandet har minskat. Då andelen patienter 
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som botas  är relativt oförändrad över tiden, talar resultaten för att Cancerregistret 
underskattar antalet nyinsjuknade gallvägscancerpatienter i Sverige. 
Studie III undersökte om risken att få gallvägscancer ökar om man får många barn eller om 
man får barn tidigt. Studien baserades på hälsoregisterdata. En ökad risk för gallvägscancer 
noterades bland kvinnor med många barn och bland kvinnor som fått barn tidigt. Emellertid 
sågs samma effekt hos män vilket talar emot en hormonell effekt. En möjlig orsak till fynden 
kan vara en påverkan av livsstilsfaktorer, såsom övervikt och rökning, som Studie III inte 
kunnat mäta. För gallblåsecancer specifikt, sågs en ökad risk hos kvinnor med lägre ålder vid 
första barnet utan motsvarande risk hos män. 
Studie IV undersökte risken att utveckla gallvägscancer hos män med prostatacancer. 
Prostatacancer behandlades tidigare med mycket höga doser av östrogen vilket gör att 
prostatacancerpatienter är en av få manliga populationer som utsatts för tillsatt östrogen. Man 
såg ingen tydligt ökad risk av gallvägscancer överlag utan snarare än lägre risk. För de 
patienter som fått högst dos av östrogen kunde en möjligt ökad risk dock ses.  
Den sista studien baserades också den på registerdata och undersökte om risken att utveckla 
gallvägscancer är förhöjd bland kvinnor som behandlas med hormonpreparat för 
övergångssymtom. Studie V visade en ökad risk för gallstenssjukdom bland 
hormonbehandlade kvinnor men kunde inte visa någon tydligt ökad risk av gallvägscancer. 
En möjligt minskad risk kunde ses bland hormonexponerade kvinnor, men resultaten kunde 
inte justeras för livsstilsfaktorer, såsom övervikt, vilket skulle kunna påverka fynden. 
14.3 Diskussion 
Studie I och II visade att många fall av gallvägscancer inte rapporteras till Cancerregistret 
samt att äldre patienter och patienter som fått diagnos i senare tidsperiod rapporteras än 
mindre ofta. En konsekvens av detta är att nyinsjuknande i gallvägscancer underskattas i 
Sverige. Förmodligen minskar nyinsjuknandet av gallvägscancer, men sannolikt inte alls lika 
mycket som man tidigare misstänkt, eller är oförändrat över tid. 
De tre sista studierna visar att könshormoners påverkan på risken att utveckla gallvägscancer 
är osäker, åtminstone verkar risken inte vara starkt ökad. För gallblåsecancer specifikt kan det 
finnas en ökad risk för kvinnor som fött många barn eller som fått barn tidigt. Vidare sågs en 
ökad förekomst av gallstenssjukdom bland kvinnor som fått hormonbehandling för 
övergångssymtom. Sannolikt behöver läkare inte ta hänsyn till risken att utveckla 
gallvägscancer när man förskriver hormonpreparat till kvinnor i övergångsåldern.  
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